US Pat. No. 10,335,464

DEVICE FOR TITRATING BASAL INSULIN

1. A device for providing a long-acting or ultra-long-acting insulin dose guidance recommendation for a subject to treat diabetes mellitus, wherein the device comprises one or more processors and a memory, the memory comprising:instructions that, when executed by the one or more processors, perform a method responsive to receiving a dose guidance request (DGR), said instructions comprising:
obtaining a first data structure that comprises at least:
(i) a body weight (BW) of the subject,
(ii) an upper limit target glucose range (UTR) of the subject,
(iii) a lower limit target glucose range (LTR) of the subject, and
(iv) an overbasalisation limit (OBL) of the subject;
obtaining a second data structure that comprises at least:
(i) a most recent adjustment day dose recommendation (ADDR), and/or
(ii) a starting basal dose (SBD);
obtaining a first data set, comprising a plurality of glucose measurements of the subject taken over a time course and thereby establish a blood glucose history (BGH) and, for each respective glucose measurement in the plurality of glucose measurements, a corresponding glucose timestamp representing when in the time course the respective glucose measurement was made;
obtaining a second data set, comprising:
(i) a basal insulin injection history (IH) of the subject, wherein the injection history comprises a plurality of injections during all or a portion of the time course and, for each respective injection in the plurality of injections,
(ii) a corresponding injection amount (IU),
(iii) an injection timestamp (UTC) representing when in the time course the respective injection occurred, and
(iv) a last injection data refresh (IDR) of the subject;
evaluating at least the first data structure, the second data structure, the first data set, and the second data set and thereby determine whether they collectively contain a set of evaluation information comprising at least:
(i) the body weight of the subject,
(ii) the plurality of glucose measurements of the subject taken over the time course,
(iii) the injection history of the subject,
(iv)
(1) the last adjustment day dose recommendation, and/or
(2) the starting long-acting or starting ultra-long-acting insulin dose of the subject,
(v) the overbasalisation limit of the subject,
(vi) the last injection data refresh for the subject,
(vii) the upper limit target glucose range of the subject, and
(viii) the lower limit target glucose range of the subject;wherein when a determination is made that the at least first data structure, second data structure, first data set, and second data set fail to collectively contain the set of evaluation information, no update to the long-acting or ultra-long-acting insulin dose guidance recommendation is made, and when a determination is made that the at least first data structure, second data structure, first data set, and second data set collectively do contain the set of evaluation information, the method further comprises providing the long-acting or ultra-long-acting insulin dose guidance recommendation.
US Pat. No. 10,337,002

MICRORNAS FOR CARDIAC REGENERATION THROUGH INDUCTION OF CARDIAC MYOCYTE PROLIFERATION

1. A method for treatment of myocardial infarction consequences, comprising administering to a subject who suffered a myocardial infarction a microRNA selected from the group consisting of:hsa-miR-590-3p (SEQ ID NO: 29), and
hsa-miR-199a-3p (SEQ ID NO: 14)or a primary transcript for such microRNA, or a precursor of such microRNA, or a mimic of such microRNA, or a combination thereof; to preserve left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS).
US Pat. No. 10,335,465

MUTANT OPAA ENZYME WITH INCREASED CATALYTIC EFFICIENCY ON ORGANOPHOSPHORUS COMPOUND GP

The United States of Amer...

1. A mutant organophosphorus acid anhydrolase (OPAA) enzyme, wherein said mutant anhydrolase enzyme comprises the amino acid sequence of SEQ ID NO: 2.
US Pat. No. 10,337,003

COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY

Sarepta Therapeutics, Inc...

1. A method of treating Duchenne muscular dystrophy (DMD) in a human subject who has a mutation of the DMD gene that is amenable to exon 51 skipping, comprising administering to the human subject a composition comprising eteplirsen and a phosphate-buffered saline at a dose of eteplirsen of about 30 mg/kg to about 50 mg/kg for a period of time sufficient to increase the number of dystrophin-positive fibers in a subject to at least 20% of normal.
US Pat. No. 10,337,004

METHODS AND COMPOSITIONS FOR TREATING A SUBJECT WITH A SMAD7 ANTISENSE OLIGONUCLEOTIDE

Nogra Pharma Limited, Du...

1. A SMAD7 antisense oligonucleotide comprising the nucleotide sequence of SEQ ID NO:11 (5?-GTCGCCCCTTCTCTCCGCAGC-3?), wherein at least one internucleotide linkage is a phosphorothioate linkage.
US Pat. No. 10,337,005

OLIGONUCLEOTIDE-BASED INHIBITORS COMPRISING LOCKED NUCLEIC ACID MOTIF

MIRAGEN THERAPEUTICS, INC...

1. An oligonucleotide comprising a sequence of 16 nucleotides, wherein the sequence is complementary to miR-29a or miR-29b or miR-29c wherein the oligonucleotide comprises no more than three contiguous locked nucleic acids (LNAs), and wherein the ratio of LNAs to non-LNA nucleic acids in the oligonucleotide is 9 to 7.
US Pat. No. 10,335,468

IMMUNOTHERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

MERCIA PHARMA, INC., New...

1. An immunotherapeutic composition for the treatment of Alzheimer's disease comprising:an immunogen comprising a peptide comprising an amino acid sequence of 7-15 consecutive amino acid residues of human amyloid beta 1-15 peptide (SEQ ID NO: 2) conjugated to an immunogenic carrier protein, formulated in a water-in-oil emulsion with an oily adjuvant vehicle comprising squalene, squalane and mannide monooleate, and polyoxyl-40-hydrogenated castor oil, wherein the immunogen is contained within aqueous globules that have a median diameter from about 100 nanometers to about 1 micron;
wherein:
the immunogenic carrier protein is diphtheria toxoid carrier;
the immunogen has a conjugation ratio of moles of peptide per mole of carrier of from about 5:1 to about 30:1;
the oily adjuvant vehicle comprises from about 85% to about 90% squalene and squalene, from about 9% to about 12% mannide monooleate and from about 0.5% to about 0.7% polyoxyl 40-hydrogenated castor oil; and
the peptide comprising the amino acid sequence of human amyloid beta protein is coupled to the immunogenic carrier protein via a spacer.
US Pat. No. 10,337,006

CHIMERIC DOUBLE-STRANDED NUCLEIC ACID

OSAKA UNIVERSITY, Osaka ...

1. A composition comprising a double-stranded nucleic acid complex comprising a first nucleic acid strand annealed to a second nucleic acid strand, wherein:(i) the first nucleic acid strand is 12 to 25 nucleotides in length, and hybridizes to a target transcription product, wherein the first nucleic acid strand comprises:
(a) a region consisting of at least 4 consecutive DNA nucleotides that are recognized by RNase H when the strand is hybridized to the target transcription product, wherein the at least 4 consecutive DNA nucleotides may be modified or unmodified;
(b) one or more nucleotide analogs located at the 5? end of the region; and
(c) one or more nucleotide analogs located at the 3? end of the region; and
(ii) the second nucleic acid strand is 12 to 31 nucleotides in length, and comprises:
(a) at least 4 consecutive RNA nucleotides; and
(b) a 5? wing region of one or more modified nucleotides, nucleotide analogs and/or modified nucleotide analogs located 5? to the at least 4 consecutive RNA nucleotides, and/or a 3? wing region of one or more modified nucleotides, nucleotide analogs and/or modified nucleotide analogs located 3? to the at least 4 consecutive RNA nucleotides, wherein the at least 4 consecutive RNA nucleotides can be cleaved by RNase H when the second nucleic acid strand is annealed with the first nucleic acid strand, and wherein the second nucleic acid strand further comprises a functional moiety having a function selected from a labeling function, a purification function, and a targeted delivery function.
US Pat. No. 10,335,470

IMMUNOGENIC COMPOSITIONS COMPRISING PROGASTRIN AND USES THEREOF

Board of Regents, The Uni...

1. A method of treating an individual having colorectal cancer expressing an Annexin II receptor, comprising:administering to the individual a pharmacologically effective amount of a composition comprising a fusion protein, wherein the fusion protein comprises 80 amino acids full length human progastrin that interacts with Annexin II receptor and promotes colorectal cancer cell proliferation, and a pharmaceutically acceptable adjuvant, wherein the administration induces an antibody response against progastrin that inhibits progastrin-induced proliferation of colorectal cancer cells in the individual, wherein the antibody blocks binding of human progastrin to an Annexin II receptor.
US Pat. No. 10,337,007

OLIGOMERIC COMPOUNDS COMPRISING BICYCLIC NUCLEOTIDES AND USES THEREOF

Ionis Pharmaceuticals, In...

1. A compound comprising:a modified oligonucleotide consisting of 16 to 20 linked nucleosides, wherein the modified oligonucleotide comprises a sugar motif of e-k-k-(D)9-k-e-k-e, wherein each “k” comprises a bicyclic nucleoside, each “e” comprises a 2?-substituted nucleoside, and each “D” comprises a 2?-deoxynucleoside; and wherein each 2?-substituent is selected from among: 2?-OMe, 2?-O-methoxyethyl, and 2?-F; and wherein the nucleobase sequence of the modified oligonucleotide is complementary to the nucleobase sequence of a target nucleic acid.
US Pat. No. 10,335,471

METHOD FOR TREATING CANCER WITH ACTIVATED T CELLS

IMMATICS BIOTECHNOLOGIES ...

1. A method for treatment of a patient with cancer, comprising administering to the patient a composition comprising a population of activated T cells that selectively recognize cancer cells that aberrantly express a peptide consisting of the amino acid sequence of RLLPKVQEV (SEQ ID NO: 325), wherein the peptide is in a complex with an MHC molecule, wherein said cancer is selected from the group consisting of glioblastoma, colorectal cancer, renal cell carcinoma, chronic lymphocytic leukemia, hepatocellular carcinoma, non-small cell and small cell lung cancer, Non-Hodgkin lymphoma, acute myeloid leukemia, pancreatic cancer, prostate cancer, esophageal cancer including cancer of the gastric-esophageal junction, gallbladder cancer and cholangiocarcinoma, melanoma, gastric cancer, testis cancer, urinary bladder cancer, head and neck squamous cell carcinoma, and uterine cancer.
US Pat. No. 10,337,008

METHODS FOR PREDICTING THE PROGRESSION AND TREATING A CHRONIC KIDNEY DISEASE IN A PATIENT

INSTITUT NATIONAL DE LA S...

1. A method of treating chronic kidney disease (CKD) in a patient in need thereof, comprisingadministering to said patient an inhibitor of Neutrophil Gelatinase-Associated Lipocalin (NGAL) gene expression, wherein said inhibitor is antisense RNA.
US Pat. No. 10,338,290

CELLULOSE ESTER FILM, POLARIZING PLATE, AND LIQUID CRYSTAL DISPLAY DEVICE

FUJIFILM Corporation, To...

1. A cellulose ester film, containing:a compound having a structural unit denoted by —NR—(C?O)— in which R represents a hydrogen atom or a substituent,
wherein a surface having knoop hardness of greater than or equal to 210 N/mm2 is provided, and
loss tangent tan ? at 25° C. is greater than or equal to 0.03.
US Pat. No. 10,337,009

SINGLE-STRANDED NUCLEIC ACID MOLECULE FOR INHIBITING TGF-?1 EXPRESSION

BONAC CORPORATION, Kurum...


(A) a single-stranded nucleic acid molecule consisting of region (X), linker region (Lx) and region (Xc) alone, wherein said region (Xc), said linker region (Lx) and said region (X) are configured in this order from the 5?-side to the 3?-side,
said linker region (Lx) has a non-nucleotide structure comprising at least one of a pyrrolidine skeleton and a piperidine skeleton, and
at least one of said region (X) and said region (Xc) consists of an additional sequence and said expression inhibitory sequence; wherein the additional sequence is GGAG or GGUG;
(B) a single-stranded nucleic acid molecule comprising region (Xc), linker region (Lx), region (X), region (Y), linker region (Ly) and region (Yc) in this order from the 5?-side to the 3?-side,
said region (X) and said region (Y) are linked to form inner region (Z),
said region (Xc) is complementary to said region (X),
said region (Yc) is complementary to said region (Y),
said linker region (Lx) and linker region (Ly) each have a non-nucleotide structure comprising at least one of a pyrrolidine skeleton and a piperidine skeleton, and
said inner region (Z) consists of an additional sequence, said expression inhibitory sequence and C, wherein the additional sequence is GGAG or GGUG.
US Pat. No. 10,338,291

MULTILAYER FILM, POLARIZATION PLATE, AND MULTILAYER FILM PRODUCTION METHOD

ZEON CORPORATION, Tokyo ...

1. A multilayer film comprising: an A layer composed of a thermoplastic resin; and a B layer disposed on at least one of the surfaces of the A layer,the B layer being composed of a material Y that contains as a main component a polymer having a glass transition temperature of ?50 to 40 ° C. , and
a thickness Ta of the A layer, a thickness Tb of the B layer, a planar orientation coefficient P of the A layer, a loss modulus Ea? of the A layer, a loss modulus Eb? of the B layer, a storage modulus Ea? of the A layer, and a storage modulus Eb? of the B layer satisfying following formulae (1) to (4):
2.5×10?3 P>1.0×10?3  (2)
Eb?>Ea?+0.01 GPa  (3)
Eb?
US Pat. No. 10,337,010

ANGIOPOIETIN-LIKE 3 (ANGPTL3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF

Alnylam Pharmaceuticals, ...

1. A double-stranded ribonucleic acid (dsRNA) agent for inhibiting expression of Angiopoietin-like 3 (ANGPTL3), wherein said dsRNA agent comprises a sense strand and an antisense strand forming a double stranded region, the antisense strand comprising a region of complementarity to an mRNA encoding ANGPTL3 which comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the complement of nucleotides 1051-1098 of SEQ ID NO:1.
US Pat. No. 10,335,474

PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CLL AND OTHER CANCERS

IMMATICS BIOTECHNOLOGIES ...

1. A method of eliciting an immune response in a patient who has cancer, comprising administering to the patient a composition comprising a population of activated T cells that selectively recognize cancer cells that present a peptide consisting of the amino acid sequence of GLDDMKANL (SEQ ID NO: 65),wherein the activated T cells are produced by contacting T cells with the peptide in complex with a human class I MHC molecule expressed on the surface of an antigen-presenting cell,
wherein said cancer is selected from the group consisting of chronic lymphocytic leukemia (CLL), acute myelogenous leukemia, bile duct cancer, brain cancer, breast cancer, colorectal carcinoma, esophageal cancer, gallbladder cancer, gastric cancer, hepatocellular cancer, Merkel cell carcinoma, melanoma, non-Hodgkin lymphoma, non-small cell lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cell cancer, small cell lung cancer, urinary bladder cancer, and uterine cancer.
US Pat. No. 10,337,011

TREATMENT OF FIBROBLAST GROWTH FACTOR 21 (FGF21) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO FGF21

CuRNA, Inc., Miami, FL (...

1. A method of identifying at least one modified oligonucleotide of 10 to 30 nucleotides in length having modulatory activity comprising: selecting a target FGF21 polynucleotide associated with a disease state; identifying at least one modified oligonucleotide comprising 10 to 30 consecutive nucleotides which are 100% complementary a natural antisense polynucleotide to the selected FGF21 target polynucleotide; measuring the thermal melting point of a hybrid of an antisense oligonucleotide and the target FGF21 natural antisense polynucleotide under stringent hybridization conditions; and determining the modulatory activity of the at least one modified oligonucleotide by measuring the increase or decrease in the target FGF21 mRNA relative to a mock-transfected control.
US Pat. No. 10,335,475

PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST NHL AND OTHER CANCERS

IMMATICS BIOTECHNOLOGIES ...

1. A method of eliciting an immune response in a HLA-A*02+ patient who has cancer, comprising administering to the patient a population of activated antigen-specific CD8+ cytotoxic T cells that kill cancer cells that present at their surface a peptide consisting of the amino acid sequence of FVIDSFEEL (SEQ ID NO: 113) in a complex with an MHC class I molecule,wherein the activated antigen-specific CD8+ cytotoxic cells are produced by a method comprising contacting in vitro CD8+ cytotoxic T cells with an antigen presenting cell presenting at its surface a peptide consisting of FVIDSFEEL (SEQ ID NO: 113) in a complex with an MHC class I molecule,
wherein said cancer is selected from the group consisting of non-Hodgkin lymphomas, chronic lymphocytic leukemia, uterine cancer, lung cancer, kidney cancer, brain cancer, stomach cancer, colon or rectal cancer, liver cancer, prostate cancer, leukemia, breast cancer, Merkel cell carcinoma (MCC), melanoma, ovarian cancer, esophageal cancer, urinary bladder cancer, endometrial cancer, gall bladder cancer, and bile duct cancer.
US Pat. No. 10,335,476

VACCINE TO PROTECT AGAINST EHRLICHIA INFECTION

THE BOARD OF REGENTS OF T...

1. A vaccine composition comprising an immunizing amount of an Ehrlichia muris sonicate, wherein the Ehrlichia muris sonicate elicits an antibody independent protective immune response within 7 days of Ehrlichia muris challenge.
US Pat. No. 10,337,013

TREATMENT OF RNASE H1 RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO RNASE H1

CuRNA, Inc., Miami, FL (...

1. A method of identifying and selecting at least one active modified antisense oligonucleotide of 10 to 30 nucleotides in length which specifically hybridizes to a natural antisense polynucleotide of a RNAse H1 gene and modulates expression of said RNAse H1 gene comprising: sequencing at least one natural antisense polynucleotide of the target RNAse H1 gene as a putative target; identifying at least one modified antisense oligonucleotide which is complementary to the natural antisense polynucleotide target; measuring the thermal melting point of a hybrid of said at least one modified antisense oligonucleotide and the target natural antisense polynucleotide under stringent hybridization conditions; and measuring the modulatory activity of said at least one modified oligonucleotide and selecting at least one active antisense oligonucleotide.
US Pat. No. 10,336,758

STABLE FORMULATIONS OF 5,10-METHYLENE-(6R)-TETRAHYDROFOLIC ACID

1. A method for treating breast cancer, esophageal cancer, gastric cancer, gall bladder cancer, bile duct cancer, colon cancer, rectal cancer, colorectal cancer, osteosarcoma, liver cancer, pancreatic cancer, ovarian cancer, head and neck cancer, mesothelioma cancer, stomach cancer, bowel cancer, or lung cancer, comprising administering an effective amount of a pharmaceutical composition to a patient in need thereof, which composition comprises:A) a hemisulfate salt of 5,10-methylene-(6R)-tetrahydrofolic acid,
B) a lyophilisate comprising the hemisulfate salt of 5,10-methylene-(6R)-tetrahydrofolic acid of A) or made therefrom,
C) a reconstituted solution from the lyophilisate of B), which has been reconstituted by water or a liquid pharmaceutically acceptable vehicle,
D) a lyophilisate comprising the sulfate salt of 5,10-methylene-(6R)-tetrahydrofolic acid or made therefrom without the presence of citrate,
E) a lyophilisate comprising 5,10-methylene-(6R)-tetrahydrofolic acid without the presence of citrate, or
F) a reconstituted solution from the lyophilisate of D) or E), which has been reconstituted by water or a liquid pharmaceutically acceptable vehicle.
US Pat. No. 10,338,039

METHOD FOR DETECTING MONOCLONAL ANTIBODY USING MASS SPECTROMETRY

SHIMADZU CORPORATION, Ky...


wherein the porous body has an average pore diameter in a range of 10 nm-200 nm, the nanoparticles have an average particle size in a range of 50 nm-500 nm, provided that the average particle size of the nanoparticles is larger than the average pore diameter of the porous body, the monoclonal antibody is trastuzumab or trastuzumab-DM1, and the peptide fragment includes the amino acid sequence of SEQ ID No: 1, 3, 6 and/or 7.
US Pat. No. 10,335,478

AVIRULENT, IMMUNOGENIC FLAVIVIRUS CHIMERAS

The United States of Amer...

1. An immunogenic composition comprising one or more live, attenuated flaviviruses comprising:(a) a nucleic acid chimera encoding:
(i) a flavivirus structural protein, wherein the flavivirus structural protein is selected from the group consisting of:
a C protein of Zika virus,
a prM protein of Zika virus,
and
an E protein of Zika virus; and
(ii) non-structural proteins from a second different flavivirus wherein the second different flavivirus comprises:
a live, attenuated dengue-2 virus containing non-conservative amino acid substitutions; or
other flavivirus genomes containing analogous mutations at the same loci as the dengue-2 virus,
wherein the chimera is avirulent; and
(b) a pharmaceutically acceptable carrier or excipient.
US Pat. No. 10,336,759

SALTS AND PROCESSES OF PREPARING A PI3K INHIBITOR

Incyte Corporation, Wilm...

1. A salt which is (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one hydrochloric acid salt, that is crystalline, having at least four XRPD peaks, in terms of 2-theta, selected from about 11.3°, about 16.4°, about 21.0°, about 23.0°, about 28.1°, about 31.2°, and about 32.8°.
US Pat. No. 10,335,479

METHODS AND COMPOSITIONS FOR STABILIZING DRIED BIOLOGICAL MATERIALS

De Staat der Nederlanden,...

1. A method for producing a formulation of a biopharmaceutical agent, comprising drying a solution comprising:(a) a biopharmaceutical agent comprising a human or bovine RSV,
(b) glutamate,
(c) a polyol comprising sorbitol and/or sucrose,
(d) at least 0.2% (w/v) of a metal salt and water, wherein the metal salt is Mg2+, and,
(e) one or more of mannitol, mannose, maltitol and/or one or more of arginine, histidine, isoleucine, asparagine, lysine, leucine, glycine.
US Pat. No. 10,335,735

METHOD OF CAPTURING CARBON DIOXIDE

National Cheng Kung Unive...

1. A method of capturing carbon dioxide from a source thereof, comprising:contacting a carbon dioxide-containing source with a reactive solution that consists of water and an absorption agent dissolved in water so that carbon dioxide in the carbon dioxide-containing source is absorbed by the absorption agent, the absorption agent being a potassium non-amino-acid monocarboxylate having a total of 12 or less carbon atoms.
US Pat. No. 10,335,480

PEPTIDE SEQUENCES AND COMPOSITIONS

PepTcell Limited, London...

1. A multi-epitope immunogenic polypeptide comprising two or more copies of two or more different influenza virus epitopes, wherein the two or more different influenza virus epitopes includes an epitope of a M1 protein from an influenza virus strain A, the epitope of the M1 protein being 8-40 amino acids in length, and a first epitope of a nucleoprotein (NP) from an influenza virus strain A, the first epitope of the NP consists of amino acids 206 to 229 of SEQ ID NO: 9.
US Pat. No. 10,336,761

TGF? RECEPTOR ANTAGONIST

Bristol-Myers Squibb Comp...

1. A compound selected fromN-[2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
3-(difluoromethyl)-N-{2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}pyridin-4-amine,
3-chloro-N-[2-(5-fluoro-6-methylpyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
3-chloro-N-[2-(5-fluoropyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine
6-{4-[(3-fluoropyridin-4-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl}pyridine-2-carboxamide,
3-chloro-N-[2-(6-methylpyrazin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
2-chloro-N-{2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}-3-fluoropyridin-4-amine,
N-(6-{4-[(pyridin-4-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl}pyridin-2-yl)methanesulfonamide,
N-(6-(4-((3-fluoropyridin-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyridin-2-yl)acetamide,
3-fluoro-N-[2-(1-methyl-1H-pyrazol-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
N-[4-({2-[6-(difluoromethyl)-5-fluoropyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridin-2-yl]acetamide,
3-fluoro-N-[2-(4-methyl-1,3-thiazol-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
N-[4-({2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridin-2-yl]acetamide,
3-fluoro-N-[2-(6-fluoropyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
3-(difluoromethyl)-N-[2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
N-[2-(6-methoxypyridin-2-yl)-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
N-(3-fluoropyridin-4-yl)-2-(4-(trifluoromethyl)thiazol-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine,
N-(4-((2-(6-(trifluoromethyl)pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)amino)pyridin-2-yl)acetamide,
N-(4-{[2-(5-fluoro-6-methylpyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}pyridin-2-yl)acetamide,
N-[3-fluoro-4-({2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridin-2-yl]acetamide,
N-[4-({2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridin-2-yl]acetamide,
N-{4-[(3-fluoropyridin-4-yl)amino]-2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-6-yl}methanesulfonamide,
N-{2-[6-(difluoromethyl)pyridin-2-yl]-5-[(4,4-difluoropiperidin-1-yl)methyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}-3-fluoropyridin-4-amine,
N-[4-({5-[(4,4-difluoropiperidin-1-yl)methyl]-2-(pyri din-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridin-2-yl]acetamide,
N-{5-[(4,4-difluoropiperidin-1-yl)methyl]-2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl}-3-fluoropyridin-4-amine,
3-fluoro-N-{5-[(4-methylpiperazin-1-yl)methyl]-2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}pyridin-4-amine,
N-{5-[(4,4-difluoropiperidin-1-yl)methyl]-2-(pyri din-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl}-3-fluoropyridin-4-amine,
1-{4-[(3-fluoropyridin-4-yl)amino]-2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl}ethane-1,2-diol,
6-ethyl-N-(3-fluoropyridin-4-yl)-2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine,
2-[4-(dimethylamino)piperidin-1-yl]-1-{4-[(3-fluoropyridin-4-yl)amino]-2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl}ethan-1-ol,
2-(6-methoxypyridin-2-yl)-N-(pyridin-4-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine,
1-(6-{4-[(3-fluoropyridin-4-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl}pyridin-2-yl)ethan-1-ol,
N-[4-({2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridin-2-yl]-2-(pyrrolidin-1-yl)acetamide,
2-N-[2-(4,4-difluoropiperidin-1-yl)ethyl]-4-N-[2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridine-2,4-diamine,
N-[2-(1,1-dioxo-1,4-thiomorpholin-4-yl)ethyl]-4-{[2-(5-fluoro-6-methylpyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}pyridine-3-carboxamide,
N-(3-(1,1-dioxidothiomorpholino)propyl)-4-((2-(6-methylpyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)amino)nicotinamide,
N-[3-(pyrrolidin-1-yl)propyl]-4-({2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridine-3-carboxamide,
N-[2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]-3-{[3-(morpholin-4-yl)propoxy]methyl}pyridin-4-amine,
2-{4-[(3-fluoropyridin-4-yl)amino]-2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-6-yl}propan-2-ol,
N-{6-[(4,4-difluoropiperidin-1-yl)methyl]-2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl}-3-fluoropyridin-4-amine,
3-fluoro-N-[7-fluoro-2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
N-[6-ethyl-2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]-3-fluoropyridin-4-amine,
3-fluoro-N-[2-(6-methoxypyridin-2-yl)-6-[4-(4-methylpiperazin-1-yl)butyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
3-fluoro-N-[2-(6-methoxypyridin-2-yl)-6-[2-(4-methylpiperazin-1-yl)ethyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
3-fluoro-N-[2-(6-methoxypyridin-2-yl)-5-[2-(pyrrolidin-1-yl)ethoxy]pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
2-{4-[(3-fluoropyridin-4-yl)amino]-2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl}ethan-1-ol,
N-(4-{[2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}pyridin-3-yl)acetamide,
2-{4-[(3-fluoropyridin-4-yl)amino]-2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl}propan-2-ol,
N-[2-(6-methylpyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
-(6-methylpyridin-2-yl)-4-[(pyridin-4-yl)amino]-N-[3-(pyrrolidin-1-yl)propyl]pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide,
3-[4-(dimethylamino)butoxy]-N-[2-(6-methylpyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
4-[(3-fluoropyridin-4-yl)amino]-2-(6-methylpyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazine-7-carboxylic acid,
2-(6-aminopyridin-2-yl)-N-(3-fluoropyridin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine,
3-chloro-N-[2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
3-fluoro-N-[2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
3-fluoro-N-[2-(6-methylpyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
3-fluoro-N-[2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
3-chloro-N-[2-(6-methylpyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
3-chloro-N-[2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
3,5-difluoro-N-[2-(6-methylpyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
3-fluoro-N-[2-(4-methylpyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
N-[2-(4-chloropyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]-3-fluoropyridin-4-amine,
N-[2-(6-methylpyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyrimidin-4-amine,
3-fluoro-N-[2-(5-fluoropyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
N-{2-[6-(difluoromethyl)-5-fluoropyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}-3-fluoropyridin-4-amine,
N-[2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyrimidin-4-amine,
Methyl N-(4-{[2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}pyridin-2-yl)carbamate,
N-[2-(5-fluoro-6-methylpyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
3-chloro-N-[2-(6-fluoropyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
3-fluoro-N-[2-(6-methylpyrazin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
3-ethyl-1-{4-[(3-fluoropyridin-4-yl)amino]-2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-6-yl}urea,
Methyl N-{4-[(3-fluoropyridin-4-yl)amino]-2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-6-yl}carbamate,
3-fluoro-N-[2-(5-fluoro-6-methylpyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
3-[3-(morpholin-4-yl)propoxy]-N-{2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}pyridin-4-amine, 75
N-{5-[(4,4-difluoropiperidin-1-yl)methyl]-2-(6-methylpyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl}-3-fluoropyridin-4-amine,
N-(6-{4-[(3-fluoropyridin-4-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl}pyridin-2-yl)methanesulfonamide,
N-{2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}-3-fluoropyridin-4-amine,
3-(prop-2-en-1-yloxy)-N-[2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
3-chloro-N-{2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}pyridin-4-amine,
3-chloro-N-[2-(1-methyl-1H-pyrazol-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
2-chloro-N-{2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}pyridin-4-amine,
4-{[2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}pyridine-3-carboxamide,
3-fluoro-N-{2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}pyridin-4-amine,
N-{2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}pyridin-4-amine,
3-chloro-N-{2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}pyridin-4-amine,
3-chloro-N-[2-(4-methyl-1,3-thiazol-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
N-[2-(4-methyl-1,3-thiazol-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
3-fluoro-N-[2-(1H-pyrrol-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
N-(6-{4-[(3-chloropyridin-4-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl}pyridin-2-yl)methanesulfonamide,
N-[5-chloro-2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
N-[2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]-2-methylpyridin-4-amine,
2-chloro-N-[2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
2-fluoro-N-[2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
4-N-[2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridine-3,4-diamine,
2-fluoro-N-[2-(6-methoxypyridin-2-yl)-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
N-(4-{[2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}pyridin-2-yl)acetamide,
4-{[2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}pyridine-3-carboxamide,
N-[2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]-2-(morpholin-4-yl)pyridin-4-amine,
3-fluoro-N-{2-[2-(trifluoromethyl)pyrimidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}pyridin-4-amine,
3-fluoro-N-[2-(2-methoxypyrimidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
N-[2-(6-ethoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]-3-fluoropyridin-4-amine,
4-N-(3-fluoropyridin-4-yl)-2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazine-4,6-diamine,
N-{4-[(3-fluoropyridin-4-yl)amino]-2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-6-yl}acetamide,
N-{4-[(3-fluoropyridin-4-yl)amino]-2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-6-yl}morpholine-4-carboxamide,
N-{4-[(3-fluoropyridin-4-yl)amino]-2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-6-yl}-2-(morpholin-4-yl)acetamide,
N-{4-[(3-fluoropyridin-4-yl)amino]-2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-6-yl}cyclopropanesulfonamide,
tert-butyl N-[({4-[(3-fluoropyridin-4-yl)amino]-2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-6-yl}carbamoyl)methyl]carbamate,
2-amino-N-{4-[(3-fluoropyridin-4-yl)amino]-2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-6-yl}acetamide,
N-{4-[(3-fluoropyridin-4-yl)amino]-2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-6-yl}-2-methanesulfonamidoacetamide,
N-{4-[(3-fluoropyridin-4-yl)amino]-2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-6-yl}-N-methanesulfonylmethanesulfonamide,
3-fluoro-N-[2-(6-methoxypyridin-2-yl)-5-[2-(4-methylpiperazin-1-yl)ethyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
3-fluoro-N-[2-(6-methoxypyridin-2-yl)-5-[2-(morpholin-4-yl)ethyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
N-{5-[2-(4-aminopiperidin-1-yl)ethyl]-2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl}-3-fluoropyridin-4-amine,
N-{2-[6-(difluoromethyl)pyridin-2-yl]-5-[(4-methylpiperazin-1-yl)methyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}-3-fluoropyridin-4-amine,
1-[({2-[6-(difluoromethyl)pyridin-2-yl]-4-[(3-fluoropyridin-4-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl}methyl)amino]-2-methylpropan-2-ol,
N-{4-[(5-{[(2-hydroxy-2-methylpropyl)amino]methyl}-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)amino]pyridin-2-yl}acetamide,
1-[({4-[(3-fluoropyridin-4-yl)amino]-2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl}methyl)amino]-2-methylpropan-2-ol,
3-fluoro-N-[2-(6-methoxypyridin-2-yl)-5-({[2-(pyrrolidin-1-yl)ethyl]amino}methyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
(3R)-3-fluoro-4-[({4-[(3-fluoropyridin-4-yl)amino]-2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl}methyl)amino]-2-methylbutan-2-ol,
3-fluoro-N-[2-(6-methoxypyridin-2-yl)-5-[(4-methylpiperazin-1-yl)methyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
N-{2-[6-(difluoromethyl)pyridin-2-yl]-5-[(4-methylpiperazin-1-yl)methyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}-3-fluoropyridin-4-amine,
N-{5-[(4,4-difluoropiperidin-1-yl)methyl]-2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}-3-fluoropyridin-4-amine,
1-[({4-[(3-fluoropyridin-4-yl)amino]-2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl}methyl)amino]-2-methylpropan-2-ol,
1-[({4-[(3-fluoropyridin-4-yl)amino]-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl}methyl)amino]-2-methylpropan-2-ol,
(3R,4R)-4-amino-1-({4-[(3-fluoropyridin-4-yl)amino]-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl}methyl)piperidin-3-ol,
3-fluoro-N-{5-[(4-methylpiperazin-1-yl)methyl]-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl}pyri din-4-amine,
1-{4-[(3-fluoropyridin-4-yl)amino]-2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl}-2-(4-methylpiperazin-1-yl)ethan-1-ol,
2-(4,4-difluoropiperidin-1-yl)-1-{4-[(3-fluoropyridin-4-yl)amino]-2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl}ethan-1-ol,
1-{4-[(3-fluoropyridin-4-yl)amino]-2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl}-2-{[2-(piperidin-1-yl)ethyl]amino}ethan-1-ol,
4-{2-[(2-{4-[(3-fluoropyridin-4-yl)amino]-2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl}-2-hydroxyethyl)amino]ethyl}-1,4-thiomorpholine-1,1-dione,
1-{2-[(4-{[2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}pyridin-2-yl)amino]ethyl}piperidin-4-ol,
1-[(4-{[2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}pyridin-2-yl)amino]-2-methylpropan-2-ol,
4-[(4-{[2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}pyridin-2-yl)amino]-2-methylbutan-2-ol,
2-N-[3-(dimethylamino)propyl]-4-N-[2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridine-2,4-diamine,
1-{2-[(4-{[2-(6-methoxypyridin-2-yl)-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}pyridin-2-yl)amino]ethyl}piperidin-4-ol,
4-N-[2-(6-methoxypyridin-2-yl)-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl]-2-N-[2-(morpholin-4-yl)ethyl]pyridine-2,4-diamine,
1-[(4-{[2-(6-methoxypyridin-2-yl)-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}pyridin-2-yl)amino]-2-methylpropan-2-ol,
4-N-[2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]-2-N-[2-(morpholin-4-yl)ethyl]pyridine-2,4-diamine,
N-[3-(1,1-dioxo-1,4-thiomorpholin-4-yl)propyl]-4-{[2-(5-fluoro-6-methylpyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}pyridine-3-carboxamide,
4-{[2-(5-fluoro-6-methylpyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}-N-[2-(piperidin-1-yl)ethyl]pyridine-3-carboxamide,
4-{[2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}-N-[2-(pyrrolidin-1-yl)ethyl]pyridine-3-carboxamide,
N-[2-(diethylamino)ethyl]-4-{[2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}pyridine-3-carboxamide,
N-[2-(piperidin-1-yl)ethyl]-4-{[2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}pyridine-3-carboxamide,
tert-butyl 4-{2-[(4-{[2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}pyridin-3-yl)formamido]ethyl}piperazine-1-carboxylate,
N-{2-[cis-2,6-dimethylmorpholin-4-yl]ethyl}-4-{[2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}pyridine-3-carboxamide,
N-[2-(1,1-dioxo-1,4-thiomorpholin-4-yl)ethyl]-4-{[2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}pyridine-3-carboxamide,
N-[3-(1,1-dioxo-1,4-thiomorpholin-4-yl)propyl]-4-{[2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}pyridine-3-carboxamide,
N-[3-(2-oxopyrrolidin-1-yl)propyl]-4-{[2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}pyridine-3-carboxamide,
4-{[2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}-N-[3-(pyrrolidin-1-yl)propyl]pyridine-3-carboxamide,
N-[2-(piperazin-1-yl)ethyl]-4-{[2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}pyridine-3-carboxamide,
4-{[2-(6-methylpyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}-N-[2-(pyrrolidin-1-yl)ethyl]pyridine-3-carboxamide,
N-[2-(1,1-dioxo-1,4-thiomorpholin-4-yl)ethyl]-4-{[2-(6-methylpyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}pyridine-3-carboxamide,
N-[(4-hydroxy-1-methylpiperidin-4-yl)methyl]-4-{[2-(6-methylpyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}pyridine-3-carboxamide,
4-{[2-(6-methylpyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}-N-[2-(piperidin-1-yl)ethyl]pyridine-3-carboxamide,
N-(2-hydroxy-2-methylpropyl)-4-{[2-(6-methylpyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}pyridine-3-carboxamide,
N-(1-hydroxy-2-methylpropan-2-yl)-4-{[2-(6-methylpyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}pyridine-3-carboxamide,
N-[(2S)-2,3-dihydroxypropyl]-4-{[2-(6-methylpyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}pyridine-3-carboxamide,
N-(3-hydroxypropyl)-4-{[2-(6-methylpyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}pyridine-3-carboxamide,
N-[3-(4-methylpiperazin-1-yl)propyl]-4-{[2-(6-methylpyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}pyridine-3-carboxamide,
4-{[2-(6-methylpyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}-N-(oxolan-3-yl)pyridine-3-carboxamide,
N-[2-(dimethylamino)ethyl]-N-methyl-4-{[2-(6-methylpyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}pyridine-3-carboxamide,
N-[2-(6-methylpyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]-3-(morpholine-4-carbonyl)pyridin-4-amine,
4-{[2-(6-methylpyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}-N-(oxan-4-yl)pyridine-3-carboxamide,
4-{[2-(6-methylpyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}-N-(oxetan-3-yl)pyridine-3-carboxamide,
4-{[2-(6-methylpyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}-N-(propan-2-yl)pyridine-3-carboxamide,
4-({2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)-N-[2-(1,1-dioxo-1,4-thiomorpholin-4-yl)ethyl]pyridine-3-carboxamide,
4-({2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)-N-[3-(1,1-dioxo-1,4-thiomorpholin-4-yl)propyl]pyridine-3-carboxamide,
N-[3-(morpholin-4-yl)propyl]-4-({2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridine-3-carboxamide,
N-[2-(pyrrolidin-1-yl)ethyl]-4-({2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridine-3-carboxamide,
N-[2-(piperidin-1-yl)ethyl]-4-({2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridine-3-carboxamide,
4-({2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)-N-(3-ethoxypropyl)pyridine-3-carboxamide,
N-[2-(tert-butoxy)ethyl]-4-({2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridine-3-carboxamide,
4-({2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)-N-[2-(2-hydroxyethoxy)ethyl]pyridine-3-carboxamide,
4-({2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)-N-[(1S,2S)-2-hydroxycyclohexyl]pyridine-3-carboxamide,
4-({2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)-N-[3-(4-methylpiperazin-1-yl)propyl]pyridine-3-carboxamide,
4-({2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)-N-(oxolan-3-yl)pyridine-3-carboxamide, 4-({2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)-N-(oxan-4-yl)pyridine-3-carboxamide,
N-[2-(1,1-dioxo-1,4-thiomorpholin-4-yl)ethyl]-4-({2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridine-3-carboxamide,
4-({2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)-N-[(1R,2R)-2-hydroxycyclohexyl]pyridine-3-carboxamide,
4-({2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)-N-(pyridin-2-ylmethyl)pyridine-3-carboxamide,
4-({2-[6-(difluoromethyl)pyri din-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)-N-[(5-ethyl-1,3,4-oxadiazol-2-yl)methyl]pyridine-3-carboxamide,
4-({2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)-N-(1,3-thiazol-2-ylmethyl)pyridine-3-carboxamide,
4-({2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)-N-propylpyridine-3-carboxamide,
1-[4-({2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridine-3-carbonyl]-4-phenylpiperidin-4-ol,
N-{2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}-3-(pyrrolidine-1-carbonyl)pyridin-4-amine,
4-({2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)-N-(3-hydroxy-3-methylbutyl)pyridine-3-carboxamide,
4-({2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)-N-(2-hydroxy-2-methylpropyl)pyridine-3-carboxamide,
3-(azetidine-1-carbonyl)-N-{2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}pyridin-4-amine,
Ethyl 2-{[4-({2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridin-3-yl]formamido}acetate,
4-({2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)-N-(1H-1,2,4-triazol-3-ylmethyl)pyridine-3-carboxamide,
4-({2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)-N-(2-hydroxyethyl)pyridine-3-carboxamide,
N-cyclobutyl-4-({2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridine-3-carboxamide,
4-({2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)-N-(propan-2-yl)pyridine-3-carboxamide,
4-({2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)-N-(1,3-oxazol-4-ylmethyl)pyridine-3-carboxamide,
tert-butyl 2-{[4-({2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridin-3-yl]formamido}acetate,
4-({2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)-N-(1H-pyrazol-5-ylmethyl)pyridine-3-carboxamide,
4-({2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)-N-[(1R,2S)-2-hydroxycyclopentyl]pyridine-3-carboxamide,
4-({2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)-N-[(1S,2S)-2-hydroxycyclopentyl]pyridine-3-carboxamide,
1-[4-({2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridine-3-carbonyl]piperidin-4-ol,
N-(4,4-difluorocyclohexyl)-4-({2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridine-3-carboxamide,
4-({2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)-N-(3,3,3-trifluoropropyl)pyridine-3-carboxamide,
N-{2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}-3-(4,4-difluoropiperidine-1-carbonyl)pyridin-4-amine,
Ethyl 3-{[4-({2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridin-3-yl]formamido}propanoate,
4-({2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)-N-{[3-(methoxymethyl)-1,2,4-oxadiazol-5-yl]methyl}pyridine-3-carboxamide,
(4-{[2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}pyridin-3-yl)methanol,
1-[({4-[(3-fluoropyridin-4-yl)amino]-2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-6-yl}methyl)amino]-2-methylpropan-2-ol,
(3R)-3-fluoro-4-[({4-[(3-fluoropyridin-4-yl)amino]-2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-6-yl}methyl)amino]-2-methylbutan-2-ol,
4-{3-[({4-[(3-fluoropyridin-4-yl)amino]-2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-6-yl}methyl)amino]propyl}-1,4-thiomorpholine-1, 1-dione,
N-[6-ethenyl-2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]-3-fluoropyridin-4-amine,
(3E)-4-{4-[(3-fluoropyridin-4-yl)amino]-2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-6-yl}but-3-en-1-ol,
N-(4-{[2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}pyridin-3-yl)-2-(morpholin-4-yl)acetamide,
N-[2-(6-fluoropyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
N-[2-(6-methoxypyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine, N-{2-[2-(methylsulfanyl)pyrimidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}pyridin-4-amine,
Ethyl 2-(6-methylpyridin-2-yl)-4-[(pyridin-4-yl)amino]pyrrolo[2,1-f][1,2,4]triazine-6-carboxylate,
2-(6-methylpyridin-2-yl)-N-phenyl-4-[(pyridin-4-yl)amino]pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide,
N,N-dimethyl-2-(6-methylpyridin-2-yl)-4-[(pyridin-4-yl)amino]pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide,
2-(6-methylpyridin-2-yl)-4-[(pyridin-4-yl)amino]pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide,
N-methyl-2-(6-methylpyridin-2-yl)-4-[(pyridin-4-yl)amino]pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide,
4-{[2-(6-methylpyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}-N-[3-(pyrrolidin-1-yl)propyl]pyridine-3-carboxamide,
N-[2-(6-methylpyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]-3-[3-(morpholin-4-yl)propoxy]pyridin-4-amine,
4-({2-[6-(difluoromethyl)-5-fluoropyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridine-3-carboxamide,
N-[4-({2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)-5-fluoropyridin-2-yl]acetamide,
N-[5-fluoro-4-({2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridin-2-yl]acetamide,
N-(4-{[2-(5-fluoropyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}pyridin-2-yl)acetamide,
4-({2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridine-3-carboxamide,
N-[4-({2-[6-(difluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)-3-fluoropyridin-2-yl]acetamide,
2-(1H-pyrazol-3-yl)-N-{2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}pyridin-4-amine,
2-[4-({4-[(3-fluoropyridin-4-yl)amino]-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl}methyl)piperazin-1-yl]ethan-1-ol,
(3S)-1-({4-[(3-fluoropyridin-4-yl)amino]-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl}methyl)pyrrolidin-3-ol,
(3R)-1-({4-[(3-fluoropyridin-4-yl)amino]-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl}methyl)pyrrolidin-3-ol,
3-fluoro-N-[2-(5-fluoropyridin-2-yl)-5-[(4-methylpiperazin-1-yl)methyl]pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
1-({[2-(5-fluoropyridin-2-yl)-4-[(3-fluoropyridin-4-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl}amino)-2-methylpropan-2-ol,
4-[({4-[(3-fluoropyridin-4-yl)amino]-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl}methyl)amino]cyclohexan-1-ol,
(5R,7S)-3-[({4-[(3-fluoropyridin-4-yl)amino]-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl}methyl)amino]adamantan-1-ol,
3-fluoro-N-(5-{[(piperidin-4-ylmethyl)amino]methyl}-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)pyridin-4-amine,
1-[({4-[(3-fluoropyridin-4-yl)amino]-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl}methyl)amino]propan-2-ol,
1-{2-[({4-[(3-fluoropyridin-4-yl)amino]-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl}methyl)amino]ethyl}cyclopentan-1-ol,
3-fluoro-N-(5-{[(1-methylcyclobutyl)amino]methyl}-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)pyridin-4-amine,
3-fluoro-N-(5-{[(4-methyloxan-4-yl)amino]methyl}-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)pyridin-4-amine,
1-({4-[(3-fluoropyridin-4-yl)amino]-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl}methyl)piperidin-4-ol,
{1-[({4-[(3-fluoropyridin-4-yl)amino]-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl}methyl)amino]cyclopentyl}methanol,
4-N-({4-[(3-fluoropyridin-4-yl)amino]-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl}methyl)-1-N, 1-N-dimethylcyclohexane-1,4-diamine,
3-fluoro-N-[5-({[3-(morpholin-4-yl)propyl]amino}methyl)-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
3-fluoro-N-(5-{[(oxolan-2-ylmethyl)amino]methyl}-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)pyridin-4-amine,
3-fluoro-N-{2-[5-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}pyridin-4-amine,
3-fluoro-N-[2-(2-methoxy-1,3-thiazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
N-{4-[(5-{[4-(2-hydroxyethyl)piperazin-1-yl]methyl}-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)amino]pyridin-2-yl}acetamide,
(3S)-1-({2-[6-(difluoromethyl)pyridin-2-yl]-4-[(3-fluoropyridin-4-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl}methyl)pyrrolidin-3-ol,
(3S)-1-({4-[(3-fluoropyridin-4-yl)amino]-2-(6-methylpyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl}methyl)pyrrolidin-3-ol,
2-[4-({2-[6-(difluoromethyl)pyridin-2-yl]-4-[(3-fluoropyridin-4-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl}methyl)piperazin-1-yl]ethan-1-ol,
N-{4-[(5-{[(2-hydroxy-2-methylpropyl)amino]methyl}-2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl)amino]pyridin-2-yl}acetamide,
N-{2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}pyrimidin-4-amine,
2-fluoro-N-{2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}pyridin-4-amine,
2-methyl-N-{2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}pyridin-4-amine,
1-{[(4-{[2-(ethylamino)pyridin-4-yl]amino}-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)methyl]amino}-2-methylpropan-2-ol,
2-[4-({4-[(3-fluoropyridin-4-yl)amino]-2-(6-methylpyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl}methyl)piperazin-1-yl]ethan-1-ol,
3-fluoro-N-[2-(3-fluoropyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
3-fluoro-N-[2-(3-fluoro-6-methylpyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
3-fluoro-N-[2-(1,3-thiazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
(1R,4R)-1-N-({4-[(3-fluoropyridin-4-yl)amino]-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl}methyl)cyclohexane-1,4-diamine,
2-[({4-[(3-fluoropyridin-4-yl)amino]-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl}methyl)amino]propane-1,3-diol,
3-fluoro-N-(5-{[(piperidin-2-ylmethyl)amino]methyl}-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)pyridin-4-amine,
N-(5-{[(azetidin-3-ylmethyl)amino]methyl}-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)-3-fluoropyridin-4-amine,
3-fluoro-N-(5-{[(piperidin-3-yl)amino]methyl}-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)pyridin-4-amine,
3-fluoro-N-[2-(pyridin-2-yl)-5-{[(2,2,2-trifluoroethyl)amino]methyl}pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
3-fluoro-N-[5-({[2-(piperazin-1-yl)ethyl]amino}methyl)-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
3-fluoro-N-[2-(pyridin-2-yl)-5-({[2-(pyrrolidin-2-yl)ethyl]amino}methyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
N-(5-{[(cyclobutylmethyl)amino]methyl}-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)-3-fluoropyridin-4-amine,
2-[({4-[(3-fluoropyridin-4-yl)amino]-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl}methyl)amino]cyclohexan-1-ol,
(2S)-2-[({4-[(3-fluoropyridin-4-yl)amino]-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl}methyl)amino]pentan-1-ol,
4-[({4-[(3-fluoropyridin-4-yl)amino]-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl}methyl)amino]butan-2-ol,
3-[4-({4-[(3-fluoropyridin-4-yl)amino]-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl}methyl)piperazin-1-yl]phenol,
3-fluoro-N-[2-(pyridin-2-yl)-5-{[4-(pyrimidin-2-yl)piperazin-1-yl]methyl}pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
1-({4-[(3-fluoropyridin-4-yl)amino]-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl}methyl)-4-phenylpiperidin-4-ol,
1-[1-({4-[(3-fluoropyridin-4-yl)amino]-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl}methyl)piperidin-4-yl]-2,3-dihydro-1H-1,3-benzodiazol-2-one,
3-fluoro-N-(5-{[methyl(1-methylpiperidin-4-yl)amino]methyl}-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)pyridin-4-amine,
N-[5-({[2-(dimethylamino)ethyl]amino}methyl)-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]-3-fluoropyridin-4-amine,
3-fluoro-N-[5-({[3-(1H-imidazol-1-yl)propyl]amino}methyl)-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
N-(5-{[(adamantan-1-yl)amino]methyl}-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)-3-fluoropyridin-4-amine,
3-fluoro-N-[5-({[3-(4-methylpiperazin-1-yl)propyl]amino}methyl)-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
3-fluoro-N-[5-({[2-(piperidin-1-yl)ethyl]amino}methyl)-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
N-[5-({[(3S)-1-benzylpyrrolidin-3-yl]amino}methyl)-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]-3-fluoropyridin-4-amine,
N-(5-{[(3-aminopropyl)amino]methyl}-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)-3-fluoropyridin-4-amine,
(2S)-3-[({4-[(3-fluoropyridin-4-yl)amino]-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl}methyl)amino]propane-1,2-diol,
(1R,4R)-4-[({4-[(3-fluoropyridin-4-yl)amino]-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl}methyl)amino]cyclohexan-1-ol,
3-fluoro-N-{2-[6-(trifluoromethoxy)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}pyridin-4-amine,
3-fluoro-N-[5-(morpholin-4-ylmethyl)-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
N-(4-{[2-(6-fluoropyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}pyridin-2-yl)acetamide,
4-({2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridine-2-carbonitrile,
N-(4-{[5-(morpholin-4-ylmethyl)-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}pyridin-2-yl)acetamide,
N-(5-{[(2H-1,3-benzodioxol-5-ylmethyl)amino]methyl}-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)-3-fluoropyridin-4-amine,
N-({4-[(3-fluoropyridin-4-yl)amino]-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl}methyl)-2-methyl-1,3-benzothiazol-6-amine,
(3-{[({4-[(3-fluoropyridin-4-yl)amino]-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl}methyl)amino]methyl}oxetan-3-yl)methanol,
3-fluoro-N-[5-({[4-(1,3-oxazol-5-yl)phenyl]amino}methyl)-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
3-fluoro-N-(5-{[(5-phenyl-1H-pyrazol-3-yl)amino]methyl}-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)pyridin-4-amine,
3-fluoro-N-(5-{[(morpholin-2-ylmethyl)amino]methyl}-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)pyridin-4-amine,
N-[5-({[(2R)-3,3-dimethylbutan-2-yl]amino}methyl)-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]-3-fluoropyridin-4-amine,
3-fluoro-N-[2-(pyridin-2-yl)-5-({[2-(pyridin-2-yl)propan-2-yl]amino}methyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
3-fluoro-N-[5-({[1-(propan-2-yl)-1H-pyrazol-4-yl]amino}methyl)-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
3-fluoro-N-[5-({[2-(1-methylpiperidin-4-yl)ethyl]amino}methyl)-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
3-fluoro-N-[2-(pyridin-2-yl)-5-({[2-(pyridin-2-yl)ethyl]amino}methyl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
3-fluoro-N-[5-({[(5-methylpyrazin-2-yl)methyl]amino}methyl)-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
N-({4-[(3-fluoropyridin-4-yl)amino]-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl}methyl)-1H-1,2,3-benzotriazol-5-amine,
3-fluoro-N-(5-{[(piperidin-4-yl)amino]methyl}-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)pyridin-4-amine,
3-fluoro-N-(5-{[(5-methyl-1,3,4-thiadiazol-2-yl)amino]methyl}-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)pyridin-4-amine,
(3S,4S)-4-amino-1-({4-[(3-fluoropyridin-4-yl)amino]-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl}methyl)piperidin-3-ol,
(1R)-2-[({4-[(3-fluoropyridin-4-yl)amino]-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl}methyl)amino]-1-phenylethan-1-ol,
N-(5-{[(azetidin-3-yl)amino]methyl}-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)-3-fluoropyridin-4-amine,
Methyl N-[4-({2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridin-2-yl]carbamate,
N-[4-({2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridin-2-yl]propanamide,
3-methyl-N-[4-({2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridin-2-yl]butanamide,
4-({2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridine-2-carboxamide,
2-(4-methylpiperazin-1-yl)-N-[4-({2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridin-2-yl]acetamide,
2-chloro-5-fluoro-N-[2-(5-fluoropyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]pyridin-4-amine,
N-[4-({2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridin-2-yl]methanesulfonamide,
2-[4-(2-hydroxyethyl)piperazin-1-yl]-N-[4-({2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridin-2-yl]acetamide,
2-(4-acetylpiperazin-1-yl)-N-[4-({2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridin-2-yl]acetamide,
3,3-dimethyl-N-[4-({2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridin-2-yl]butanamide,
2-(piperazin-1-yl)-N-[4-({2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridin-2-yl]acetamide,
N-(5-fluoro-4-{[2-(5-fluoropyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}pyridin-2-yl)acetamide,
N-(2-hydroxy-2-methylpropyl)-4-({2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridine-2-carboxamide,
2-[(3S)-3-hydroxypyrrolidin-1-yl]-N-[4-({2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridin-2-yl]acetamide,
(2S)—N-[4-({2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridin-2-yl]pyrrolidine-2-carboxamide,
2-[(3R)-3-hydroxypyrrolidin-1-yl]-N-[4-({2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridin-2-yl]acetamide,
3-fluoro-N-(5-{[(1-methylpiperidin-4-yl)oxy]methyl}-2-(pyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)pyridin-4-amine,
2-(piperidin-1-yl)-N-[4-({2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridin-2-yl]acetamide,
2-[(2-hydroxy-2-methylpropyl)amino]-N-[4-({2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridin-2-yl]acetamide,
2-(morpholin-4-yl)-N-[4-({2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridin-2-yl]acetamide,
N-[4-({2-[5-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridin-2-yl]acetamide,
N-(5-fluoro-4-{[2-(5-fluoro-6-methylpyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}pyridin-2-yl)acetamide,
3-[(3R)-3-hydroxypyrrolidin-1-yl]-N-[4-({2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridin-2-yl]propanamide,
N-[4-({2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridin-2-yl]cyclopropanecarboxamide,
2-methoxy-N-[4-({2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridin-2-yl]acetamide,
4,4,4-trifluoro-N-[4-({2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridin-2-yl]butanamide,
3-cyano-N-[4-({2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridin-2-yl]propanamide,
N-(5-fluoro-4-{[2-(6-fluoropyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}pyridin-2-yl)acetamide,
3-(4-hydroxypiperidin-1-yl)-N-[4-({2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridin-2-yl]propanamide,
3-(3,3-difluoroazetidin-1-yl)-N-[4-({2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridin-2-yl]propanamide,
2,2-dimethyl-N-[4-({2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridin-2-yl]propanamide,
3-methoxy-N-[4-({2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridin-2-yl]propanamide,
3,3,3-trifluoro-N-[4-({2-[6-(trifluoromethyl)pyridin-2-yl]pyrrolo[2,1-f][1,2,4]triazin-4-yl}amino)pyridin-2-yl]propanamide,
N-(4-{[2-(5-fluoro-6-methylpyridin-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl]amino}pyridin-2-yl)cyclopropanecarboxamide,
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
US Pat. No. 10,338,042

APPARATUS AND METHOD FOR INVESTIGATING DISCONTINUOUS PRODUCT FLUID STREAMS IN THE REACTION OF REACTANT FLUID STREAMS OVER SOLID CATALYSTS

hte GmbH the high through...

1. An apparatus suitable for investigating solid catalysts and processes in which discontinuous fluid streams arise, the apparatus comprising:a reactant fluid supply point;
at least one reaction space;
at least one fluid mixing space;
at least one throttle element;
at least one pressure control valve; and
at least one analyzer,
wherein an outlet side of the at least one reaction space is connected to a connecting line, and an end of the connecting line is separated into a substream line and an exit line such that the outlet side of the at least one reaction space is operatively connected to the at least one fluid mixing space via the connecting line and the substream line and to an exit air line via the connecting line and the exit line,
the at least one fluid mixing space is connected to the at least one throttle element,
the at least one throttle element is operatively connected to the at least one analyzer and an outlet line,
the connecting line is operatively connected to the at least one pressure control valve and the exit air line, and
the at least one pressure control valve is arranged either downstream or upstream of the substream line and, when the at least one pressure control valve is upstream of the substream line, the outlet line is provided with a second pressure control valve and a pump.
US Pat. No. 10,335,481

GENE-MODIFIED MEASLES VIRUS FOR TUMOR TREATMENT USE

THE UNIVERSITY OF TOKYO, ...

1. A pharmaceutical composition for use in the treatment of cancer, comprising:rMV-V(?)-SLAM-blind.
US Pat. No. 10,335,482

METHOD OF INDUCING AN ANTI-HIV-1 IMMUNE RESPONSE COMPRISING ADMINISTERING A C5/TM-GP41 PEPTIDE DIMER

BIONOR IMMUNO AS, Skien ...

1. A method for inhibiting human immunodeficiency virus type 1 (HIV-1) replication by inducing an anti-HIV-1 immune response in a human infected with HIV-1, the method comprising(1) administering an effective amount of a peptide dimer of formula A-chain: (H-Gly-Ala-Lys-Arg-Arg-Val-Val-Gly-Gly-Cys(2-oxo-ethyl)-Gly-Gly-Ala-Lys-Arg-Arg-Val-Val-Gln-Arg-Glu-Lys-Arg-Ala-Gly-Glu-Arg-Glu-Lys-Arg-Ala-NH2) and B-chain: (H-Gly-Lys-Gly-Gly-Ile-Glu-Glu-Glu-Gly-Gly-Arg-Asp-Arg-Asp-Arg-Gly-Gly-Gln-Asp-Arg-Asp-Arg-NH2), in the form of an acetate salt with an amide bond between Cys(2-oxo-ethyl)10 (A-chain) and Lys2 (B-chain)), and
(2) administering the HIV-1-specific peptides of SEQ ID NO: 49, SEQ ID NO: 52, SEQ ID NO: 57, and SEQ ID NO: 64, or salts thereof,
wherein the peptide dimer and HIV-1 specific peptides are administered to a human infected with HIV-1.
US Pat. No. 10,336,763

CRYSTAL FORM B OF RIBOCICLIB SUCCINATE

3. A pharmaceutical composition comprising at least one pharmaceutically acceptable vehicle, diluent and/or excipient and a crystalline form B of ribociclib succinate having a characteristic X-ray powder diffraction pattern comprising peaks at 2? values of 12.9°±0.20°, 13.7°±0.20°, 18.7°±0.20°, 19.9°±0.20° and 23.0°±0.20°.
US Pat. No. 10,335,483

COMPOSITION FOR ENHANCING INDUCTION OF HUMORAL IMMUNITY, AND VACCINE PHARMACEUTICAL COMPOSITION

NITTO DENKO CORPORATION, ...

1. A method for promoting humoral immunity induction in a subject in need thereof, comprising:administering to the subject an effective amount of a G protein-coupled receptor (GPCR) ligand that is at least one selected from an antagonist for a Gi-coupled GPCR and an antagonist for a Gq-coupled GPCR.
US Pat. No. 10,335,484

METHODS OF GENERATING ROBUST PASSIVE AND ACTIVE IMMUNE RESPONSES

HUMABS BIOMED SA, Bellin...

1. A method of generating an active immune response in a subject, comprising administering to said subject an effective amount of an influenza A neutralizing monoclonal antibody sequentially with an influenza A antigen, wherein:(a) said influenza A antigen is administered between about 1 hour to about 3 weeks following administration of said monoclonal antibody; or
(b) said monoclonal antibody is administered between about 1 hour to about 3 weeks following administration of said influenza A antigen; and
wherein said influenza A antigen is an attenuated virus or a recombinant vaccine.
US Pat. No. 10,337,021

METHODS OF MODULATING SEED AND ORGAN SIZE IN PLANTS

Plant Bioscience Limited,...

1. A method of increasing the yield of a plant comprising:expressing a nucleic acid encoding a DA1 protein within cells of said plant, wherein the DA1 protein comprises an amino acid sequence having at least 90% sequence identity to one or more of SEQ NOS: 4 to 27, wherein the amino acid sequence of the DA1 protein comprises a mutation that disrupts or inactivates the LIM domain of the DA1 protein,
wherein the LIM domain of the DA1 protein comprises one or more sequence alterations relative to the wild-type LIM domain of SEQ ID NO: 1 which inactivate the LIM domain, wherein the wild-type LIM domain comprises two Zn finger motifs and the sequence alterations abolish one or both Zn finger motifs, wherein the plant has increased yield compared to a plant without the mutation grown in the same conditions, and wherein increased yield comprises increased organ size and/or seed size.
US Pat. No. 10,335,485

ANTI-VLA-4 ANTIBODIES

Biogen MA Inc., Cambridg...

1. A recombinant anti-?4 antibody molecule, or ?4-binding fragment thereof, comprising: (a) a variable light chain comprising the amino acid sequence of SEQ ID NO: 11; and (b) a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 4.
US Pat. No. 10,337,022

METHODS OF INCREASING ROOT BIOMASS IN PLANTS

AgResearch Limited, Hami...

1. A method for at least one of:a) increasing root biomass in a plant, and
b) producing a plant increased root biomass,the method comprising the step of increasing the expression of at least one PEAPOD protein, or fragment thereof, in the plant.
US Pat. No. 10,335,486

MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER

ModernaTX, Inc., Cambrid...

1. A method for treating cancer in a subject by inducing or enhancing an anti-tumor immune response, comprising administering to the subject a first messenger RNA (mRNA) encoding an IL-23 polypeptide comprising an IL-12p40 polypeptide operably linked, with or without a linker, to an IL-23p19 polypeptide, a second mRNA encoding an IL-18 polypeptide, and a third mRNA encoding an OX40L polypeptide, thereby treating cancer in the subject by inducing or enhancing an anti-tumor immune response.
US Pat. No. 10,337,023

ISOLATED POLYNUCLEOTIDES AND POLYPEPTIDES, AND METHODS OF USING SAME FOR INCREASING PLANT YIELD AND/OR AGRICULTURAL CHARACTERISTICS

Evogene Ltd., Rehovot (I...

1. A method of increasing seed yield, growth rate, and/or biomass of a plant, the method comprising:(a) transforming plants with an exogenous polynucleotide comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence having at least 95% amino acid sequence identity to the amino acid sequence as set forth in SEQ ID NO: 1011, and,
(b) selecting a plant from step (a) which is transformed with said exogenous polynucleotide, overexpressing said polypeptide and exhibiting an increased dry weight, leaf blade area, leaf number, plot coverage, relative growth rate of leaf number, relative growth rate of plot coverage, relative growth rate of rosette diameter, harvest index, seed yield, rosette area, or rosette diameter as compared to a wild type plant of the same species which is grown under the same growth conditions, thereby increasing the seed yield, growth rate, and/or biomass of the plant.
US Pat. No. 10,338,048

FOOD FRESHNESS INDICATOR INK AND METHOD FOR THE MANUFACTURE OF A FOOD FRESHNESS INDICATOR INK

1. A food freshness indicator ink, which comprises:i) a varnish that constitutes between 90-98 weight % of the total ink, said varnish comprising
i.1) between 5-25 weight % of the total amount of the varnish of at least one film-forming resin or at least one vinylic resin or a mixture thereof;
i.2) between 10-25 weight % of the amount of the resin of a plasticiser additive; and
i.3) between 50-75 weight % of the total amount of the varnish of solvents, and
ii) between 2-10 weight % of the total ink being metallic salts.
US Pat. No. 10,337,024

PLANTS WITH ENHANCED PHOTOSYNTHESIS AND METHODS OF MANUFACTURE THEREOF

THE UNIVERSITY OF MASSACH...

1. A transgenic plant transformed with a recombinant DNA construct comprising a plant-expressible transcription regulatory sequence operatively linked to a polynucleotide encoding an algal CCP1 or CCP2 polypeptide comprising an amino acid sequence that is at least 80% homologous to SEQ ID NO: 6, wherein the transgenic plant has a CO2 assimilation rate at least 5% higher than a plant of the same species not transformed with the recombinant DNA construct anda reduced transpiration rate at least 5% lower than a plant of the same species not transformed with the recombinant DNA construct.
US Pat. No. 10,335,488

METHOD FOR TREATING CANCER BY PHOTODYNAMIC THERAPY

D. R. NANO CO., LTD., Se...

1. A method for treating of cancer using methylene blue nanoparticles, the method comprising steps of:a) administrating a therapeutic agent containing the methylene blue nanoparticles into a tissue;
b) applying light irradiation to the tissue;
c) generating a singlet oxygen from the methylene blue nanoparticles; and
d) inducing cell apoptosis and reducing cancer area,
wherein each of the methylene blue nanoparticles comprises a methylene blue-fatty acid complex and an amphiphilic copolymer of pluronic F-68,
wherein the amphiphilic copolymer comprises a polyoxyethylenepolyoxypropylene-polyoxyethylene block copolymer;
the methylene blue-fatty acid complex is enclosed in a micelle formed by the amphiphilic copolymer; and
each of the methylene blue nanoparticles has a diameter of 80 to 100 nm and is self-assembled in an aqueous environment.
US Pat. No. 10,337,025

CHROMOBACTERIUM SUBTSUGAGE GENES

Marrone Bio Innovations, ...

1. A a recombinant vector comprising a heterologous promoter operably linked to a nucleotide sequence encoding a polypeptide with 100% identity to SEO ID NO: 1.
US Pat. No. 10,337,026

PHI-4 POLYPEPTIDES AND METHODS FOR THEIR USE

PIONEER HI-BRED INTERNATI...

1. A variant polypeptide comprising the amino acid sequence of SEQ ID NO: 35 having an amino acid substitution at position 281 of SEQ ID NO: 35 selected from Glu or Lys, wherein the variant polypeptide has at least 1.3 fold increased insecticidal activity against Western Corn Root Worm (WCRW) larvae compared to the polypeptide of SEQ ID NO: 35.
US Pat. No. 10,337,027

METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND THE PREVENTION OF CARDIOMYOPATHY DUE TO FRIEDREICH ATAXIA

CORNELL UNIVERSITY, Itha...

1. A method for treating cardiomyopathy in a subject with Friedreich ataxia in need thereof, the method comprising administering by intravenous injection to said subject a therapeutically effective amount of a vector which comprises nucleic acid encoding a frataxin (FXN) operably linked to regulatory sequences, wherein the vector is an AAVrh10 vector.
US Pat. No. 10,337,028

NUCLEIC ACID-GUIDED NUCLEASES

Inscripta, Inc., Boulder...

1. A nucleic acid-guided nuclease system comprising:(a) a nucleic acid-guided nuclease comprising the amino acid sequence of SEQ ID NO: 7;
(b) a heterologous engineered guide nucleic acid for complexing with the nucleic acid-guided nuclease, wherein said heterologous engineered guide comprises a pseudoknot region comprising nucleotide residues 17-26 of SEQ ID NO: 200 or nucleotide residues 17-26 of SEQ ID NO: 201, and
(c) an editing sequence having a change in sequence relative to the sequence of a target region; wherein the system results in an edit in the target region facilitated by the nuclease, the heterologous guide nucleic acid, and the editing sequence.
US Pat. No. 10,336,773

NEPRILYSIN INHIBITORS

1. (2R,4R)-5-Biphenyl-4-yl-4-[(5-carboxymethyl-1H-pyrazole-3-carbonyl)amino]-2-hydroxy-pentanoic acid or a pharmaceutically acceptable salt thereof.
US Pat. No. 10,337,029

METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION

The Regents of the Univer...

1. A method of targeting and binding a target DNA, the method comprising:introducing a composition comprising a protein-RNA complex into a cell, wherein the cell comprises the target DNA and the protein-RNA complex comprises:
(a) a Cas9 protein; and
(b) a single molecule DNA-targeting RNA comprising, in 5? to 3? order:
(i) a targeter-RNA comprising a nucleotide sequence that is complementary to, and hybridizes with, a target sequence of the target DNA; and
(ii) an activator-RNA that hybridizes with the targeter-RNA to form a double-stranded RNA duplex,
wherein (i) and (ii) are covalently linked by intervening nucleotides,
wherein said protein-RNA complex binds to the target DNA.
US Pat. No. 10,335,493

TARGETED PROTEASE COMPOSITIONS AND USES RELATED THERETO

Emory University, Atlant...

1. A composition comprising a conjugate comprising a targeting molecule,wherein the conjugate further comprises a protease polypeptide having a catalytic domain,
wherein the targeting molecule comprises SEQ ID NO: 2, and
wherein the catalytic domain comprises SEQ ID NO: 5.
US Pat. No. 10,335,494

COMBINATION OF AURORA KINASE INHIBITORS AND ANTI-CD30 ANTIBODIES

Millennium Pharmaceutical...

1. A method of treating a patient suffering from a lymphoma, comprising administering to the subject a therapeutically effective amount of 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid or a pharmaceutically acceptable salt thereof simultaneously with or consecutively with a therapeutically effective amount of brentuximab vedotin,wherein the 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid or pharmaceutically acceptable salt thereof is administered on each of days 1-3 and 8-10 of a 21-day cycle, or each of days 1-3, 8-10, and 15-17 of a 28-day cycle; and wherein the brentuximab vedotin is administered on day 1 of a 21-day cycle.
US Pat. No. 10,337,031

PRODUCTION OF FRAGRANT COMPOUNDS

Firmenich SA, Geneva (CH...

1. A method of producing one or more sesquiterpenes comprising (+)-cedrol and/or (?)-thujopsene, the method comprising:a. contacting an acyclic farnesyl diphosphate (FPP) precursor with a polypeptide having a (+)-cedrol synthase activity and/or a (?)-thujopsene synthase activity wherein the polypeptide comprises:
i. a sequence of amino acids that has at least 90% sequence identity to a polypeptide selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO: 13 and SEQ ID NO: 14; or
ii. a sequence of amino acids selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO: 13 and SEQ ID NO: 14,
to produce one or more sesquiterpenes comprising (+)-cedrol and/or (?)-thujopsene; and
b. optionally isolating the (+)-cedrol and/or (?)-thujopsene.
US Pat. No. 10,335,238

SYSTEM AND METHOD FOR NON-INVASIVELY ESTIMATING ELECTROPHYSIOLOGICAL MAPS AND MEASUREMENTS FROM CARDIO-THORACIC 3D IMAGES AND ELECTROCARDIOGRAPHY DATA

Siemens Healthcare GmbH, ...

1. A method for non-invasively simulating patient-specific cardiac electrophysiology, comprising:generating a patient-specific anatomical heart model from medical image data of a patient;
computing torso potentials over time at locations on a torso of the patient using the patient-specific anatomical heart model, a patient-specific anatomical arrangement between the heart and torso, and a cardiac electrophysiology model with certain model parameters;
estimating patient-specific model parameters of the cardiac electrophysiology model by refining the model parameters of the cardiac electrophysiology model to minimize an error between the computed torso potentials and body surface potential measurements acquired for the patient;
simulating patient-specific electrophysiological measurements including transmembrane potentials in a myocardium of the patient-specific anatomical heart model, extra-cellular potentials, and torso potentials using the cardiac electrophysiology model with the patient-specific model parameters; and
generating at least one of a visualization of the simulated patient-specific electrophysiological measurements or patient-specific electrophysiology parameter maps based on the patient-specific anatomical heart model, the patient-specific anatomical arrangement between the heart and torso, and the cardiac electrophysiology model with the patient-specific model parameters.
US Pat. No. 10,337,032

COMPOSITIONS AND METHODS FOR RECOMBINANT BIOSYNTHESIS OF PROPANE

THE UNIVERSITY OF MANCHES...

1. A genetically engineered bacterium, which expresses both an enzyme for butyraldehyde synthesis and a heterologous polypeptide having aldehyde deformylating oxygenase activity and produces propane from butyraldehyde as a precursor independent of fatty acid synthesis pathways where the genetically engineered bacterium is Escherichia coli.
US Pat. No. 10,337,034

BIOMASS CONVERSION TO FUELS AND CHEMICALS

Alliance for Sustainable ...

1. A process for producing adipic acid, the process comprising:contacting a culture broth comprising a lignin depolymerization compound with a genetically modified prokaryotic microorganism comprising a first exogenous genetic addition encoding at least a 3-dehydroshikimate dehydratase and a phenol monooxygenase, wherein the genetically modified prokaryotic microorganism converts at least a portion of the lignin depolymerization compound to cis, cis-muconic acid;
separating the cis, cis-muconic acid from the culture broth;
purifying the separated cis, cis-muconic acid; and
hydrogenating at least a portion of the purified cis, cis-muconic acid to produce the adipic acid.
US Pat. No. 10,338,060

METHODS FOR MONITORING PHYSIOLOGICAL STATUS OF A BODY ORGAN

BioCrine AB, Solna (SE)

1. A method for monitoring status of in situ pancreatic islets in a human subject that has a disease relating to the pancreas, comprising monitoring changes over time in pancreatic islets of Langerhans transplanted on an eye of the subject, wherein the changes over time in the transplanted pancreatic islets of Langerhans indicate status of in situ pancreatic islets in the subject.
US Pat. No. 10,335,499

BLOCK COPOLYMERS AND USES THEREOF

1. A block copolymer comprising a hydrophilic block and a hydrophobic block, wherein said hydrophilic or hydrophobic block is interrupted with a hydrolysable chemical moiety,wherein said hydrophilic block comprises poly(ethylene glycol), poly(ethylene oxide), poly(vinyl alcohol), poly(ethylene-co-vinyl alcohol), poly(N-vinyl pyrrolidone), poly(acrylic acid), poly(ethyloxazoline), poly(alkylacrylates), poly(acrylamide), poly(N-alkylacrylamides), polysaccharide, poly(N,N-dialkylacrylamides), hyaluronic acid, or poly (N-acryloylmorpholine), and
said hydrophobic block comprises poly(propylene sulfide), poly(propylene glycol), esterified poly(acrylic acid), esterified poly(glutamic acid), or esterified poly(aspartic acid); and
wherein said hydrolysable chemical moiety is not a block.
US Pat. No. 10,337,036

PROCESSES FOR STARTING UP AND OPERATING DEEP TANK ANAEROBIC FERMENTATION REACTORS FOR MAKING OXYGENATED ORGANIC COMPOUND FROM CARBON MONOXIDE AND HYDROGEN

Synata Bio, Inc., Warren...

1. A process for anaerobic bioconversion of a gas substrate comprising carbon monoxide, hydrogen, and carbon dioxide in a reactor having a liquid capacity of at least 1 million liters by contact of the gas substrate with an aqueous menstruum containing microorganisms suitable for converting the gas substrate to an oxygenated organic compound in the reactor, the process further comprising:(a) blanketing the reactor above the aqueous menstruum to the essential exclusion of oxygen with a head space gas comprising at least one of carbon monoxide, hydrogen, carbon dioxide, nitrogen, and a lower alkane;
(b) continuously supplying a feed gas comprising at least a portion of the gas substrate to the aqueous menstruum in the reactor; and
(c) injecting the gas substrate and a motive liquid into the reactor to form a dispersion of the motive liquid and microbubbles, the microbubbles having a non-zero diameter of less than about 500 microns.
US Pat. No. 10,335,500

HIGHLY STABLE BIODEGRADABLE GENE VECTOR PLATFORMS FOR OVERCOMING BIOLOGICAL BARRIERS

The Johns Hopkins Univers...

1. A formulation of colloidally stable nanoparticles for delivery of nucleic acids across biological barriers, the nanoparticles comprising(a) a polymer blend comprising poly (?-amino ester) (PBAE) and PBAE conjugated to a hydrophilic, neutrally charged polymer comprising polyethylene glycol or a copolymer thereof,
wherein the ratio of non-PEGylated PBAE to PBAE conjugated to polyethylene glycol or a copolymer thereof is between 25 and 1, and
and an effective amount of the polyethylene glycol is on the surface of the particle to create a near neutral surface charge, and
(b) nucleic acids complexed with the non-pegylated PBAE,
wherein the nucleic acids are encapsulated within the nanoparticle or are associated with the surface of the nanoparticle, and
the nanoparticles are less than 100 nm in size.
US Pat. No. 10,337,037

METHOD OF PRODUCING LIPID

Kao Corporation, Tokyo (...

1. A method comprising the steps of:culturing a transformant in which the expression of a gene encoding protein (A) or (B) is enhanced, and
improving the ratio of the amount of long-chain fatty acids or the amount of ester compound thereof, in the total amount of all fatty acids, or the total amount of fatty acid esters consisting of the ester compounds thereof, wherein:
protein (A) is a protein consisting of the amino acid sequence set forth in SEQ ID NO: 1; and
protein (B) is a protein consisting of an amino acid sequence having 92% or more identity with the amino acid sequence of the protein (A), and having ?-ketoacyl-ACP synthase activity wherein the transformant is an algal cell.
US Pat. No. 10,337,038

MICROORGANISMS AND METHODS FOR THE PRODUCTION OF FATTY ACIDS AND FATTY ACID DERIVED PRODUCTS

CARGILL, INCORPORATED, W...

1. A genetically modified organism comprising a heterologous nucleic acid sequence encoding a NphT7 polypeptide and a wax ester synthase,wherein said microorganism produces a fatty acid or fatty acid-derived product having a carbon chain length of C4 or greater, and
wherein the NphT7 polypeptide comprises one or more amino acid substitutions at a position selected from the group consisting of Ser84, Val114, Gly288, Ile194, Gly318, Thr85, Gln90, Val196, Tyr144, Phe159, Ile147, and Phe217.
US Pat. No. 10,335,502

FREEZE-DRIED FORMULATION FOR GAS-FILLED MICROVESICLES

Bracco Suisse SA, Manno ...

1. A freeze-dried powder composition for the preparation of gas-filled microvesicles, said composition comprising a phospholipid and a polyethylene glycol, wherein said polyethylene glycol has a percentage of folded polymeric chains higher than 34% and lower than 80%.
US Pat. No. 10,336,783

SOLID CATALYST FOR HYDRIDE ISOMERIZATION REACTION IN AN AQUEOUS MEDIUM

JAPAN SCIENCE AND TECHNOL...

1. A method for selectively producing fructose as a produced product from glucose as a raw material, the method comprising:conducting a catalytic hydride isomerization reaction from glucose to fructose in the presence of a solid catalyst in water or in an aqueous solution,
obtaining the produced product from the water or the aqueous solution,
wherein the solid catalyst consists essentially of a Group 13 element oxide whose surface is bonded with a phosphoric acid to form a structure of —O—P(O)(OH)2 with the Group 13 element oxide.
US Pat. No. 10,337,040

PROCESS FOR ENZYMATIC HYDROLYSIS OF LIGNOCELLULOSIC MATERIAL AND FERMENTATION OF SUGARS

DSM IP ASSETS B.V., Heer...

1. A process for the preparation of a sugar product from lignocellulosic material, comprising:enzymatic hydrolysis and oxidation of the lignocellulosic material in the presence of an enzyme composition comprising at least two cellulases and a lytic polysaccharide monooxygenase (LPMO);
adding 20-10,000 mmol of oxygen per kg glucan to the lignocellulosic material during the enzymatic hydrolysis;
wherein the enzymatic hydrolysis is conducted until at least 70% of available sugar in the lignocellulosic material is released; and
wherein at the end of the enzymatic hydrolysis the amount of gluconic acid formed during oxidation of the lignocellulosic material is kept between 3 to 10 g/kg glucan present in the lignocellulosic material.
US Pat. No. 10,337,041

COMPOSITIONS FOR PRODUCING GLUCOSE SYRUPS

1. A composition comprising an alpha-amylase, a pullulanase and a glucoamylase, whereinthe alpha-amylase has at least 90% sequence identity to SEQ ID NO: 5 or a mature polypeptide thereof,
the pullulanase has at least 90% sequence identity to SEQ ID NO: 16 or a mature polypeptide thereof,
the glucoamylase has at least 90% sequence identity to SEQ ID NO: 4 or a mature polypeptide thereof, and
the ratio of pullulanase dose in New Pullulanase Units Novozymes (NPUN)/gDS to alpha-amylase dose in Acid Fungal Alpha-amylase Units (FAU(A))/gDS is at least 60 and the ratio of pullulanase dose in New Pullulanase Units Novozymes (NPUN)/gDS to glucoamylase dose in Glucoamylase Units (AGU)/gDS is in the range of 2-15.
US Pat. No. 10,338,066

MEASUREMENT OF PROTEIN EXPRESSION USING REAGENTS WITH BARCODED OLIGONUCLEOTIDE SEQUENCES

Cellular Research, Inc., ...

1. A method of measuring protein expression in cells, comprising:(a) contacting a plurality of oligonucleotide-conjugated antibodies with a plurality of cells comprising a plurality of protein targets, wherein each of the plurality of oligonucleotide-conjugated antibodies comprises an antibody conjugated with an antibody specific oligonucleotide comprising a unique identifier for the antibody conjugated therewith and a poly(A) tail, and wherein the antibody is capable of specifically binding to at least one of the plurality of protein targets;
(b) partitioning the plurality of cells associated with the plurality of oligonucleotide-conjugated antibodies to a plurality of partitions, wherein a partition of the plurality of partitions comprises a single cell from the plurality of cells associated with the oligonucleotide-conjugated antibodies;
(c) in the partition comprising the single cell, contacting a barcoding particle with the antibody specific oligonucleotides, wherein the barcoding particle comprises a plurality of oligonucleotide probes each comprising a poly(T) region and a barcode sequence selected from a diverse set of unique barcode sequences;
(d) extending the oligonucleotide probes hybridized to the antibody specific oligonucleotides via the hybridization between the poly(A) tails of the antibody specific oligonucleotides and the poly(T) regions of the oligonucleotide probes to produce a plurality of labeled nucleic acids, wherein each of the labeled nucleic acid comprises a unique identifier, or a complementary sequence thereof, and a barcode sequence; and
(e) obtaining sequence information of the plurality of labeled nucleic acids or a portion thereof to determine the quantity of one or more of the plurality of protein targets in one or more of the plurality of cells.
US Pat. No. 10,336,018

METHOD OF MAKING A GOLF BALL INCORPORATING AT LEAST ONE ELONGATED THERMOSET LAYER

Acushnet Company, Fairha...

1. A method of making a golf ball comprising:providing a subassembly;
providing a thermoset polymer composition;
stepwise elongating the thermoset polymer composition by at least the steps of:
(i) stretching the thermoset polymer composition in at least one plane while the thermoset polymer composition is in a partial cure state and before forming the thermoset polymer composition into first and second half shells; and
(ii) forming the thermoset polymer composition into first and second half shells and elongating the thermoset polymer composition in three dimensions while the thermoset polymer composition is in the partial cure state and before mating the first and second half shells about the subassembly;
mating the first and second half shells about the subassembly and forming a stepwise-elongated thermoset layer.
US Pat. No. 10,336,786

PHARMACEUTICAL TARGETING OF A MAMMALIAN CYCLIC DI-NUCLEOTIDE SIGNALING PATHWAY

Board of Regents, The Uni...

1. A composition comprising an immunogen and an adjuvant, wherein the adjuvant is a cyclic dinucleotide comprising a 5?-monophosphate nucleotide comprising a guanine moiety, and a 5?-monophosphate nucleotide comprising an adenine moiety, wherein the cyclic dinucleotide hasa phosphodiester bond between the 2?-OH of the nucleotide comprising the guanine moiety and the 5?-phosphate of the nucleotide comprising the adenine moiety, and
a phosphodiester bond between the 3?-OH of the nucleotide comprising the adenine moiety and the 5?-phosphate of the nucleotide comprising the guanine moiety.
US Pat. No. 10,338,067

RAPID ANALYSIS FOR CYANOBACTERIAL TOXINS

Abraxis, Inc., Warminste...

1. A method of releasing a cyanobacterial toxin in a suspension comprising cyanobacteria suspended in an aqueous medium, wherein said method comprises adding a releasing agent to an aliquot of the suspension so as to release toxins from the bacteria into the medium, provided the cyanobacteria are not subjected to a freeze-thaw step before, during, or after the step where the releasing agent is added to the suspension, wherein the releasing agent is a metal salt that comprises a copper atom and which can dissociate in water to release the copper atom as a copper ion, and wherein the releasing agent is selected from the group consisting of copper acetate, copper benzoate, copper bromide, copper chloride, copper chlorate, copper fluoride, copper formate, copper nitrate, copper perchlorate, and copper sulfate.
US Pat. No. 10,337,043

CARBOHYDRATE-ENRICHED RECOMBINANT MICROORGANISMS

CALYSTA, INC., Menlo Par...

1. A recombinant methanotrophic bacterium, comprising an exogenous nucleic acid that encodes a glucan synthase,wherein the recombinant methanotrophic bacterium is capable of producing glucan at a level that is greater than that produced by the parent methanotrophic bacterium; and
wherein the methanotrophic bacterium is selected from the group consisting of Methylomonas, Methylobacter, Methylococcus, Methylosinus, Methylocystis, Methylomicrobium, Methanomonas, and Methylocella.
US Pat. No. 10,336,788

INHIBITION OF CARDIAC FIBROSIS IN MYOCARDIAL INFARCTION

MOERAE MATRIX, INC., Mor...

1. A method for treating ischemia-mediated apoptosis in a peri-infarct border zone in a subject that has suffered a myocardial infarction (MI), the method comprising administering to the subject in need of such treatment a therapeutic amount of a pharmaceutical composition comprising a polypeptide of amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or a functional equivalent thereof selected from the group consisting of a polypeptide of amino acid sequence FAKLAARLYRKALARQLGVAA (SEQ ID NO: 4), KAFAKLAARLYRKALARQLGVAA (SEQ ID NO: 5), YARAAARQARAKALARQLAVA (SEQ ID NO: 6), YARAAARQARAKALARQLGVA (SEQ ID NO: 7) and HRRIKAWLKKIKALARQLGVAA (SEQ ID NO: 8); and a pharmaceutically acceptable carrier,wherein
the MI is characterized by aberrant deposition of an extracellular matrix protein, an aberrant promotion of fibroblast proliferation in the heart, an aberrant induction of myofibroblast differentiation, an aberrant promotion of attachment of myofibroblasts to an extracellular matrix or a combination thereof;
wherein when tested in vitro under hypoxic conditions, the pharmaceutical composition is effective to inhibit apoptotic cell death of ventricular cardiomyocyte cells when measured at 16 and 24 hours and atrial cardiomyocyte cells when measured at 12 hours, compared to control cells harvested at initiation of hypoxia challenge;
and
the therapeutic amount of the pharmaceutical composition is effective to inhibit apoptotic cell death of cardiomyocytes in the peri-infarct zone, wherein without the therapeutic effect, ventricular remodeling can progress to heart failure.
US Pat. No. 10,337,044

KANAMYCIN COMPOUND, KANAMYCIN-PRODUCING STREPTOMYCES SPECIES BACTERIUM, AND METHOD OF PRODUCING KANAMYCIN

iNtRON Biotechnology, Inc...

1. A vector for producing 1-N-AHBA-kanamycin comprising a gene set ofkanA, kanB, kanK, kanF, kacA, kanE, kanC, kanD, btrG, btrH, btrI btrJ, btrK, btrO, and btrV.
US Pat. No. 10,338,069

GLYCAN ARRAYS FOR HIGH THROUGHPUT SCREENING OF VIRUSES

ACADEMIA SINICA, Taipei ...

1. A method for detecting at least one influenza serotype in a sample suspected of or comprising one or more viruses, the method comprising the steps of:a) providing a substrate having at least one type of glycan capture probe bound at a discrete location on the substrate, wherein the capture probes can bind to a specific influenza serotype target;
b) providing at least one type of nanoparticle probe conjugated to a detector moiety, wherein the detector moiety binds to the specific influenza serotype;
c) contacting the substrate with the sample suspected of comprising one or more viruses and the nanoparticle probe under conditions suitable for the binding of the glycan capture probes to the specific influenza serotype and the binding of the nanoparticle probe to the specific influenza serotype to form a complex at the discrete location on the substrate; and
d) detecting the presence or absence of the complex wherein the presence or absence of the complex is indicative of the presence or absence of the specific influenza serotype in the sample;
wherein the nanoparticle consists essentially of a noble metal, and
wherein the limit of detection of at least one influenza serotype in said sample suspected of or comprising one or more viruses is less than 104 viral particles.
US Pat. No. 10,336,789

PEPTIDES CAPABLE OF REACTIVATING P53 MUTANTS

Yeda Research and Develop...

1. A recombinant or synthetic peptide comprising an amino-acid sequence selected from the group consisting of SEQ ID NO:319, 320, 316, 318 and 297,wherein said peptide at least partially reactivates a mutant p53 protein; and
wherein said peptide is up to 30 amino-acids in length.
US Pat. No. 10,337,045

METHODS AND MEANS FOR THE PRODUCTION OF IG-LIKE MOLECULES

Merus N.V., Utrecht (NL)...

1. A composition comprising a mixture of at least two different antibodies, wherein one antibody in the mixture comprises a 1st antibody heavy chain comprising at least one substitution of a neutral amino acid residue in the CH3 domain by a positively charged amino acid residue as compared to wildtype, and a 2nd antibody heavy chain comprising at least one substitution of a neutral amino acid residue, as compared to wildtype, in the CH3 domain by a negatively charged amino acid residue, and wherein the positively charged amino acid residue of the first heavy chain interacts with the negatively charged amino acid residue the second heavy chain at the interface between the first and second heavy chains.
US Pat. No. 10,337,046

HIGH CONFIDENCE IN POSITIVE STATUS DETERMINATION

BECTON, DICKINSON AND COM...

1. A method comprising:(A) incubating, with an incubator, a culture disposed within a vessel during portions of a time interval between a first time point and a second time point, wherein the culture comprises a sample and a culture media;
(B) measuring, with a sensor, a biological state of the culture at a plurality of time points between the first time point and the second time point, wherein the biological state is one of CO2 concentration, O2 concentration, pH, a rate of change in CO2 concentration, a rate of change in O2 concentration, or a rate of change in pH;
(C) determining, with one or more processors, a plurality of rate transformation values, wherein each rate transformation value is derived from a different subset of the measurements of the biological state of the culture within a predetermined time interval;
(D) determining, with the one or more processors, a plurality of average relative transformation values, wherein each average relative transformation value is derived from a different subset of the rate transformation values;
(E) determining, with the one or more processors, that the culture contains a plurality of microorganisms when (i) at least one average relative transformation value exceeds a first threshold value or (ii) an extent of growth exhibited by the culture exceeds a second threshold value, wherein the extent of growth is derived from one or more of the measurements of the biological state of the culture; and
(F) processing the vessel to confirm the presence of the plurality of microorganisms after it is determined in step (E) that the culture contains a plurality of microorganisms.
US Pat. No. 10,335,766

SUPER ABSORBENT POLYMER AND MANUFACTURING METHOD THEREOF

LG Chem, Ltd., (KR)

1. A super absorbent polymer comprising:super absorbent polymer particles and
silica coated on a surface of the super absorbent polymer particles, wherein
i) a surface area of the silica is 90 to 380 m2/g; and
ii) a content of the silica relative to total weight of the super absorbent polymer particles is 0.05 to 0.3 wt %,
wherein the super absorbent polymer has a gel strength of 5000 Pa to 7500 Pa, a porosity of 25% or more, and a free swell gel bed permeability (FS GBP) of 20 darcy or more.
US Pat. No. 10,336,791

MEANS AND METHODS FOR MEDIATING PROTEIN INTERFERENCE

VIB VZW, Ghent (BE) VRIJ...

1. A non-naturally occurring molecule down-regulating the biological function of a target protein, comprising a beta-aggregation region fused to a moiety,wherein the beta-aggregation region consists of at least 6 contiguous amino acids,
wherein the moiety is a peptide or a protein domain,
wherein the non-naturally occurring molecule has a specificity for the target protein, and
wherein the non-naturally occurring molecule is obtained by the steps comprising:
i) acquiring the amino acid sequence of said target protein;
ii) determining an aggregation propensity score and identifying a beta-aggregation region within the amino acid sequence of said target protein;
iii) isolating the beta-aggregation region from the amino acid encoding sequence of said target protein; and
iv) covalently linking the isolated beta-aggregation region to a moiety to obtain said non-naturally occurring molecule, wherein said peptide or protein domain is not present in the target protein.
US Pat. No. 10,335,511

BIOADHESIVE FOR OCCLUDING VESSELS

Covidien LP, Mansfield, ...

1. A method of treating a vascular malformation of a mammal, the method comprising:injecting a bioadhesive into a vascular malformation of a mammal to displace blood in the malformation and prevent blood flow back into the malformation and to crosslink the bioadhesive in the malformation to form an occlusion in the malformation,
wherein the bioadhesive comprises: (i) a biopolymer having one or more first chemically reactive amine groups; (ii) a biocompatible crosslinker having at least two second chemically reactive groups that can chemically react with the one or more first chemically reactive amine groups of the biopolymer; and (iii) a biocompatible rheological modifier, and
wherein the biopolymer and crosslinker form a crosslinked network and the biocompatible rheological modifier does not substantially react with the biopolymer or the biocompatible crosslinker.
US Pat. No. 10,335,767

SOL-GEL POLYMERIC STATIONARY PHASES FOR HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY AND SOLID PHASE EXTRACTION: THEIR METHOD OF MAKING

THE FLORIDA INTERNATIONAL...

1. A method of preparing a sol-gel sorbent or chromatography stationary phase, comprising:providing a mixture of metal oxide precursors, water and, optionally, a solvent;
providing a polymer comprising at least one hydroxyl group and, optionally, the solvent or a second solvent;
providing an acid catalyst;
mixing the metal oxide precursors, the water, the polymer, the acid catalyst, and, optionally, the solvent and optionally, the second solvent to form a hydrolysis mixture;
providing a basic catalyst and optionally the solvent, the second solvent, or a third solvent;
adding the basic catalyst and optionally the solvent, the second solvent, or a third solvent to the hydrolysis mixture to form a gelation mixture;
optionally, warming the gelation mixture;
holding the gelation mixture until a gel forms; and
crushing or grinding the gel to form particles of a metal oxide gel containing polymeric segments uniformly distributed throughout the metal oxide gel, wherein the particles are a sol-gel sorbent or chromatography stationary phase.
US Pat. No. 10,337,048

METHODS FOR UNIVERSAL DETERMINATION OF ANTICOAGULANT ACTIVITY

Roche Diagnostics Operati...

1. A method for determining an anticoagulant activity elicited by a first anticoagulant in a sample of a subject comprising:(a) measuring a first Factor Xa activity in a body fluid test sample of said subject, said body fluid test sample containing a first anticoagulant;
(b) measuring a second Factor Xa activity in at least one calibrator sample comprising a predefined anticoagulation activity for a second anticoagulant, said second anticoagulant being a chemically different compound than the first anticoagulant; and
(c) calculating a value of a universal parameter for the anticoagulation activity comprised in the test sample based on the first and the second measured Factor Xa activities by (i) allocating a calibration value of said universal parameter to said second measured Factor Xa activity; (ii) comparing the first Factor Xa activity to the second Factor Xa activity; and (iii) from the result of comparing step (ii), deriving said value of the universal parameter for the first Factor Xa activity from said calibration value.
US Pat. No. 10,338,073

LYMPH NODE SPECIMEN COLLECTION KIT AND METHOD OF PATHOLOGICAL ANALYSIS FOR LUNG CANCER DIAGNOSIS USING SUCH A KIT

1. A method of lung cancer diagnosis based upon the consideration of cancerous growth within specific types of lymph nodes in relation to their mediastinal stations, wherein said method comprising the steps of:A) supplying at least one specimen collection kit including twelve separate collection containers provided within at least one enclosure with a lid, wherein each collection container includes a preservative solution and a removable lid, and wherein each collection container is coded in association with a specific station of each and every lymph node to be removed from a subject patients mediastinal region and placed within each suitably coded collection container;
B) removing by a surgeon at least one lymph node from each specifically pre-identified coded mediastinal station of said subject patient, wherein such lymph node removal may be accomplished through any available surgical method;
C) placing by the surgeon each removed lymph node within said preservative solution within its appropriately coded collection container, thereby indicating each different type of removed lymph node present within the collection containers in relation to the actual mediastinal location from which each of said removed lymph nodes was present, and placing the appropriate container lid in sealing fashion on each container after placement of each lymph node therein;
D) providing a pathologist with said at least one specimen collection kit with said properly coded collection containers including the correlated removed lymph nodes in order to permit analysis of each removed lymph node for degree of cancerous growth and/or activity in relation to the mediastinal location of each such lymph node and in relation to any known cancerous growths within the same mediastinal area;
wherein said collection containers of said kit are appropriately coded in terms of target lymph node station through specific colors, numbers, location names, or any combination or combinations thereof;
and wherein said kit includes a checklist for communicating removal of each lymph node and the placement within its appropriately coded collection container and if the placement does not occur said checklist providing a manner of indication any reason said surgeon did not place each lymph node within its appropriately coded collection container to said pathologist; and
E. having the surgeon communicate removal of each lymph node and the placement within its appropriately coded collection container and if the lacement does not occur with the pathologist through the use of the checklist.
US Pat. No. 10,335,512

DERMAL FILLER BASED ON CROSSLINKED HYALURONIC ACID AND CARBOXYMETHYL CELLULOSE LUBRICANT

1. An injectable dermal filler composition in the form of a gel, comprising crosslinked hyaluronic acid and uncrosslinked carboxymethyl cellulose, wherein the crosslinked hyaluronic acid is crosslinked with 1,4-butanediol diglycidyl ether (BDDE), wherein the composition further comprises calcium hydroxyapatite microparticles in a concentration of 20% to 40% volume/volume, and wherein the carboxymethyl cellulose is present at a concentration of 5.0% to 20% volume/volume.
US Pat. No. 10,338,074

COMPOSITIONS, METHODS AND KITS FOR DIAGNOSIS OF LUNG CANCER

Biodesix, Inc., Boulder,...

1. A method of determining the likelihood that a pulmonary nodule in a subject is not lung cancer, comprising:(a) contacting a blood sample obtained from the subject with a proteolytic enzyme to produce peptide fragments from a panel of proteins present in the blood sample, wherein the panel comprises LG3BP and C163A;
(b) combining the produced peptide fragments from the panel from step (a) with labeled, synthetic peptide fragments which correspond to the produced peptide fragments from the panel;
(c) performing selected reaction monitoring mass spectrometry to measure the abundance of the peptide fragments from step (b);
(d) calculating a probability of lung cancer score based on the peptide fragment measurements of step (c); and
(e) ruling out lung cancer for the subject if the score in step (d) is lower than a pre-determined score.
US Pat. No. 10,336,794

IMMUNOGENIC BACTERIAL VESICLES WITH OUTER MEMBRANE PROTEINS

GLAXOSMITHKLINE BIOLOGICA...

1. A process for preparing Escherichia bacterial vesicles, comprising the steps of: (i) culturing an Escherichia bacterium in a culture medium such that the bacterium releases vesicles into said medium; and (ii) collecting the vesicles from said medium, wherein: (a) the bacterium has a cell wall that includes peptidoglycan; and (b) the bacterium has a knockout mutation of its mltA gene.
US Pat. No. 10,337,050

POLYPHENOLIC ADDITIVES IN SEQUENCING BY SYNTHESIS

Qiagen Sciences, LLC, Ge...

7. A kit, comprising i) a cleave reagent comprising i) a reducing agent, ii) a polyphenolic compound selected from the group consisting of gallic acid, gentisic acid, pryocatechol, and pyrogallol and iii) a plurality of nucleotide analogues wherein at least a portion of said nucleotide analogues is labeled with a label attached through a cleavable disulfide linker to the base.
US Pat. No. 10,338,075

LUNG CANCER MARKERS AND USES THEREOF

Celera Corporation, San ...

1. A method for detecting an elevated lung cancer biomarker panel, the method comprising detecting the levels of tissue factor pathway inhibitor (TFPI) protein, carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) protein, Cyfra 21-1 (Cyfra) protein, squamous cell carcinoma antigen (SCC) protein, and osteopontin (OPN) protein in a body fluid sample from a human, detecting said elevated lung cancer biomarker panel when the level of at least one of said proteins is elevated, and administering a therapeutic agent to treat lung cancer to said human when said elevated lung cancer biomarker panel is detected.
US Pat. No. 10,335,514

COMPOSITION, CELL STRUCTURE, PANCREATIC ISLET TRANSPLANTATION KIT, PANCREATIC ISLET CELL TRANSPLANTATION TREATMENT AGENT AND HYPOGLYCEMIC AGENT, COMPOSITION CONTAINING PANCREATIC ISLET, KIT CONTAINING PANCREATIC ISLET, AND PANCREATIC ISLET TRANSPLANTATION

FUJIFILM Corporation, To...

1. A composition comprising:(A): a cell structure which contains a biocompatible macromolecular block and at least one kind of cell and in which a plurality of the macromolecular blocks are arranged in gaps between a plurality of the cells; and
(B): a pancreatic islet,
wherein said biocompatible macromolecular block is a polypeptide, and said at least one kind of cell comprises a mesenchymal stem cell, and said pancreatic islet is an aggregate of a ? cell, a ? cell, a ? cell, a ? cell and a PP cell.
US Pat. No. 10,336,795

SYSTEM AND METHOD FOR PRODUCING PHYCOCYANIN

University of Newcastle, ...

1. A system for producing increased levels of phycocyanin, the system comprising a vessel and a lamp, wherein the lamp provides a source of light, wherein the light consists of electromagnetic radiation consisting of a wavelength of between 670 and 690 nm, and wherein the vessel further comprises a cyanobacteria in a growth medium, and wherein the cyanobacteria synthesizes increased levels of phycocyanin compared to that of cyanobacteria separately cultured in the presence of white light.
US Pat. No. 10,337,051

METHODS AND COMPOSITIONS FOR DETECTING A TARGET RNA

The Regents of the Univer...

1. An acellular in vitro method of detecting a single stranded target RNA in a sample, the method comprising:a) contacting the sample in vitro with:
(i) a C2c2 guide RNA that hybridizes with the single stranded target RNA;
(ii) a first labeled detector RNA comprising at least one uracil;
(iii) a second labeled detector RNA lacking uracil; and
(iv) a C2c2 protein that cleaves the first labeled detector RNA and does not cleave the second labeled detector RNA,
wherein the C2c2 protein comprises an amino acid sequence having 80% or more amino acid sequence identity with the amino acid sequence set forth in SEQ ID NO:2 or SEQ ID NO:6, and
wherein, before said contacting step, the sample comprises a plurality of RNAs that differ from one another in nucleotide sequence; and
b) measuring a detectable signal produced by cleavage of the first labeled detector RNA, wherein said measuring provides for detection of the single-stranded target RNA in the sample.
US Pat. No. 10,338,076

METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF OVARIAN CANCER

The Wistar Institute of A...

1. A method for diagnosing or detecting or monitoring the progress or treatment of ovarian cancer in a subject comprising:contacting a sample obtained from a test subject with a diagnostic reagent consisting of
(a) a ligand capable of specifically complexing with, binding to, or quantitatively detecting or identifying the biomarker chloride intracellular channel protein 4 (CLIC4) or an isoform, pro-form, modified molecular form, posttranslational modification, or unique peptide fragment or unique nucleic acid fragment thereof;
(b) a ligand capable of specifically complexing with, binding to, or quantitatively detecting or identifying the biomarker chloride intracellular channel protein 1 (CLIC1) or an isoform, pro-form, modified molecular form, posttranslational modification, or unique peptide fragment or unique nucleic acid fragment thereof; and
(c) a ligand capable of specifically complexing with, binding to, or quantitatively detecting or identifying the biomarker cathepsin D-30 (CTSD-30) or an isoform, pro-form, modified molecular form, posttranslational modification, or unique peptide fragment or unique nucleic acid fragment thereof; and
one or more additional ligands, each additional ligand capable of specifically complexing with, binding to, or quantitatively detecting, or identifying an additional biomarker that indicates the presence of ovarian cancer in a human subject, wherein said additional biomarker is selected from:
i. tropomyosin 1 (TPM1);
ii. tropomyosin 2 (TPM2);
iii. tropomyosin 3 (TPM3);
iv. tropomyosin 4 (TPM4);
v. proteasome subunit alpha type-7 (PSMA7)
vi. CA125; and
vii. HE4,
(ii) detecting or measuring in the sample or from a protein level profile generated from the sample, the protein levels of the selected biomarkers;
(iii) comparing the protein level of the selected biomarkers in the subject's sample with the level of the same biomarkers in a reference standard;
wherein a significant change in the protein level of one or more of the selected biomarkers in the subject's sample from that in the reference standard indicates a diagnosis, risk, or the status of progression or remission of ovarian cancer in the subject.
US Pat. No. 10,337,052

METHOD FOR TESTING A MUTANT GENE THROUGH REAL TIME POLYMERASE CHAIN REACTION USING INHIBITION OF 5?-FLAP ENDONUCLEASE ACTIVITY

GENOTECH CORP., Daejeon ...

1. A method of determining a mutation of a gene, the method comprising:providing a template DNA for testing, the template DNA comprising a DNA strand that contains a pre-identified potential SNP location in its sequence;
performing a real-time PCR of the template DNA in the presence of a first primer, a second primer, a DNA polymerase, and a probe to provide a PCR product strand which comprises a primer portion originating from the first primer and a polymerized portion extending from the primer portion, in which the polymerized portion comprises a base at a location corresponding to the pre-identified potential SNP location of the DNA strand,
wherein the probe is configured to enable fluorescence resonance energy transfer (FRET),
wherein the probe comprises a first portion and a second portion that extends from the first portion to a 5?-end of the probe,
wherein the first portion of the probe is designed to be complementary to at least part of the first primer such that the probe hybridizes to the PCR product strand during the real-time PCR,
wherein the second portion of the probe is designed to comprise a first base at the 5?-end of the probe and a second base next to the first base such that the second base corresponds to the base of the PCR product strand at the location corresponding to the pre-identified potential SNP location of the DNA strand and further such that the first base is not complementary to its corresponding base of the PCR product strand,
wherein, when the probe hybridizes to the PCR product strand during the real-time PCR, the first base and the second base of the second portion provide a flap with one base at the 5?-end of the probe if the template DNA does not have a mutation at the pre-identified potential SNP location,
wherein, when the probe hybridizes to the PCR product strand during the real-time PCR, the first base and the second base of the second portion provide a flap with two or more bases at the 5?-end of the probe if the template DNA has a mutation at the pre-identified potential SNP location,
wherein the DNA polymerase has a 5?-flap endonuclease (FEN) activity for a flap with one base while the 5?-flap endonuclease (FEN) activity is inhibited for a flap with two or more bases,
wherein when the probe has a flap with one base, the DNA polymerase hydrolyzes the flap with one base and performs DNA polymerization during the real-time PCR, which will generate a FRET signal,
wherein when the probe has a flap with two or more bases, the 5?-flap endonuclease (FEN) activity of the DNA polymerase is inhibited and does not perform DNA polymerization during the real-time PCR, which does not generate a FRET signal,
determining that the template DNA does not have a mutation at the pre-identified potential SNP location if a FRET signal is detected; and
determining that the template DNA does have a mutation at the pre-identified potential SNP location if a FRET signal is not detected.
US Pat. No. 10,338,077

METHODS FOR DETERMINING DRUG EFFICACY FOR TREATMENT OF CANCER RATION OF CEREBLON ASSOCIATED PROTEINS

CELGENE CORPORATION, Sum...

1. A method of treating a cancer with lenalidomide in a subject, comprising:(a) obtaining a sample from the subject;
(b) measuring mRNA level of cereblon (CRBN);
(c) measuring mRNA level of IKZF1;
(d) determining the ratio of the mRNA level of CRBN to the mRNA level of IKZF1; and
(e) diagnosing the subject as being likely to be responsive to lenalidomide if the ratio of the mRNA level of CRBN to the mRNA level of IKZF1 is higher than 3;
(f) administering lenalidomide to the subject diagnosed as being likely to be responsive to lenalidomide,
wherein the cancer is an Adult T-cell Leukemia (ATL).
US Pat. No. 10,335,516

BIOACTIVE POROUS BONE GRAFT IMPLANTS

PROSIDYAN, INC., New Pro...

1. A porous, composite bone graft implant, comprising:at least one cluster comprising a matrix of randomly oriented bioactive glass fibers and bioactive glass particulates comprising microspheres distributed throughout the bioactive glass fibers, at least some of the fibers and particulates being sintered together, and a bioactive shell comprising bioactive glass at least partially encasing, and at least partially sintered to, the matrix; wherein the fibers, particulates and shell each have a different resorption rate.
US Pat. No. 10,335,772

CATALYST COMPRISING GOLD HOMOGENEOUSLY DISPERSED IN A POROUS SUPPORT

IFP Energies Nouvelles, ...

1. A process for the preparation of a catalyst wherein the catalyst comprises particles of gold and a porous support containing at least one refractory oxide, in which a content of the particles of gold is in the range of 0.01% to 5% by weight with respect to the total weight of the catalyst, and in which the particles of gold are distributed homogeneously through said porous support and have a dimension, measured by transmission electron microscopy, in the range of 0.5 to 5 nm wherein said process comprising the following steps:a) preparing an aqueous solution containing a precursor of the particles of gold;
b) impregnating the porous support containing the at least one refractory oxide with said solution obtained in step a)
c) maturing the impregnated porous support obtained in step b) in order to obtain a catalyst precursor;
d) bringing the catalyst precursor obtained in step c) into contact with a solution containing urea;
e) drying the catalyst precursor obtained in step d) at a temperature in the range of 70° C. to 300° C. to obtain the catalyst.
US Pat. No. 10,336,797

RECOMBINANT FILAGGRIN POLYPEPTIDES FOR CELL IMPORTATION

Research Development Foun...

1. A recombinant polypeptide comprising (a) a filaggrin amino acid sequence; and (b) a cell importation signal sequence comprising a motif of two to fifteen amino acids, wherein the motif comprises at least one arginine residue and at least one methionine residue, wherein the polypeptide comprises SEQ ID NO:21 or SEQ ID NO:22.
US Pat. No. 10,335,773

FE-BASED HYDROGENATION CATALYST AND USE THEREOF

1. A Fe-based hydrogenation catalyst, consisting of:Fe as a primary active metal component;
zinc and potassium as a first co-active metal component, and
a second co-active element component selected from titanium, zirconium, phosphorus, vanadium, cobalt, nickel, palladium and platinum,
wherein, based on the total weight of the Fe-based hydrogenation catalyst, a total amount of the primary active metal component and co-active element components is 5-100%, with the balance being a binder or carrier, in terms of oxides, and wherein the co-active element components comprise the first co-active metal component and the second co-active element component,
wherein the primary active metal component to the first co-active metal component has a molar ratio that is 0.5-200:1,
wherein the molar ratio of the primary active metal component to the second co-active element component is 0.5-200:1.
US Pat. No. 10,336,798

GROWTH DIFFERENTIATION FACTOR 15 (GDF-15) POLYPEPTIDES

1. A fusion protein comprising:(a) a GDF15 polypeptide comprising an amino acid sequence that is at least 95 percent identical to SEQ ID NO: 4, 8, 12, or 14; and
(b) a negatively charged Fc sequence comprising a lysine-to-aspartate mutation.
US Pat. No. 10,336,799

FIBROBLAST GROWTH FACTOR MUTEINS WITH INCREASED ACTIVITY

Miltenyi Biotec GmbH, Be...

1. A fibroblast growth factor-two (FGF-2) polypeptide that differs from the wild-type FGF-2 (SEQ ID NO:1) at least at amino acid positions 56, 102 and 119, wherein the differences are Q56I, N102G and K119N substitutions, and wherein said FGF-2 polypeptide has a higher thermostability, higher biological activity and higher resistance to proteolytic degradation than wild-type FGF-2.
US Pat. No. 10,338,080

METHODS AND COMPOSITIONS FOR DETECTION OF COMPLEMENT FIXING ANTIBODIES

The Board of Trustees of ...

1. A method for determining the presence or absence of complement fixing antibodies in a biological sample from a subject that bind specifically to human leukocyte antigens (HLAs), the method comprising:incubating a biological sample from a subject with a collection of microparticles of different subtypes and exogenous complement factor C1q, wherein each microparticle is coated with a different purified HLA subtype and wherein the incubating is for a sufficient time to allow anti-HLA complement fixing antibodies in the biological sample to bind to the HLAs and to allow the exogenous complement factor C1q to bind the anti-HLA complement fixing antibodies in the biological sample;
prior to performing any washing step, incubating the microparticles with at least one detectably labeled ligand that specifically binds directly to the exogenous complement factor C1q bound to the anti-HLA complement fixing antibodies bound to the HLAs; and
detecting the presence or absence of the detectably labeled ligand bound to the exogenous complement factor C1q to determine the presence or absence of complement fixing antibodies.
US Pat. No. 10,336,800

THERAPEUTIC USE OF BONE MORPHOGENETIC PROTEINS

CAMBRIDGE ENTERPRISE LIMI...

1. A vector comprising a nucleotide sequence encoding a bone morphogenetic protein 9 (BMP9) variant having endothelial cell signaling activity and lacking osteogenic activity, wherein the difference between the amino acid sequence of said BMP9 variant and the amino acid sequence of SEQ ID NO: 4 consists of a substitution selected from the group consisting of F362A, D366A, I375A, L379A, S402A, D408A, Y416A and Y418A.
US Pat. No. 10,337,056

DYNAMIC FLUX NUCLEIC ACID SEQUENCE AMPLIFICATION

1. A real-time dynamic flux method of nucleic acid sequence amplification, comprising:a. combining a pair of forward and reverse oligonucleotide primers with a target nucleic acid sequence to be amplified; and
b. amplifying the target nucleic acid sequence by thermocycling the pair of forward and reverse oligonucleotide primers and the target nucleic acid sequence within a 15° C. temperature range defined by the melting temperature of the oligonucleotide primers and the melting temperature of the target nucleic acid sequence, and
wherein thermocycling comprises:
i. denaturing the target nucleic acid sequence; and
ii. annealing of the forward and reverse oligonucleotide primers; and
iii. extension of the target nucleic acid sequence by the forward and reverse oligonucleotide primers,
c. simultaneously detecting the amplified target nucleic acid sequence during said amplifying step.
US Pat. No. 10,336,801

CHEMOKINE-CYTOKINE FUSION PROTEINS OF SDF-1 AND CD40L

NATIONAL CHUNG HSING UNIV...

1. A fusion protein, comprising:a chemokine polypeptide, wherein the chemokine polypeptide is stromal cell-derived factor-1; and
a cytokine polypeptide connected to the chemokine polypeptide by a peptide linker,
wherein the peptide linker is a hydrophilic helical peptide linker,
wherein the cytokine polypeptide is CD40 ligand, and
wherein the fusion protein has an amino acid sequence selected from the group consisting of SEQ ID NOs: 46 and 48.
US Pat. No. 10,335,777

ZSM-5 CATALYST

BASF Corporation, Florha...

1. ZSM-5 zeolite microspheres formed by 1) shaping a mixture into microspheres wherein the mixture comprises a silica material and a plurality of particulates selected from the group consisting of at least one high-density material with an absolute bulk density of at least 0.3 g/cc, ZSM-5 zeolite crystals, and combinations thereof; 2) calcining the microspheres; and 3) reacting and subsequently heating the microspheres with at least one alkali solution to form ZSM-5 zeolite in-situ on the microspheres, wherein the ZSM-5 zeolite microspheres contain substantially no clay or calcined clay material.
US Pat. No. 10,336,802

ACYLATED GLUCAGON ANALOGUE

1. A compound having the formula:R1-H-Aib-QGTFTSDYSKYLDERAAKDFIEWLE-K([17-Carboxy-heptadecanoyl]-isoGlu-GSGSGG)-A-R2  (SEQ ID NO: 1)whereinR1 is H (hydrogen), C1-4 alkyl, acetyl, formyl, benzoyl or trifluoroacetyl; and
R2 is OH or NH2;or a pharmaceutically acceptable salt thereof.
US Pat. No. 10,338,083

PATHWAY SPECIFIC MARKERS FOR DIAGNOSING IRRITABLE BOWEL SYNDROME

NESTEC S.A., Vevey (CH)

1. A method for determining irritable bowel syndrome (IBS) in a subject from a microbiome score and treating the subject in need thereof, the method comprising:(a) detecting in a sample from said subject a panel of markers comprising one or more antibodies against a bacterial antigen selected from the group consisting of Ec0Flic, CjFlaB, SfFliC, EcEra, EcGabT, RbCpaF, PrOmpA and combinations thereof;
(b) calculating a microbiome score based upon the presence or level of said panel of markers using a statistical algorithm to determine if the subject has IBS; and
(c) administering to the subject having IBS a therapeutic drug to treat IBS.
US Pat. No. 10,335,778

CATALYST FOR PRODUCING GAMMA-VALEROLACTONE, METHOD FOR PREPARING THE SAME AND METHOD FOR MANUFACTURING GAMMA-VALEROLACTONE USING THE SAME

KOREA INSTITUTE OF SCIENC...

1. A catalyst for producing gamma-valerolactone, comprising Beta zeolite substituted with a metal; anda heteropolyacid supported on the zeolite.
US Pat. No. 10,336,803

INSULIN SECRETING POLYPEPTIDES

Mayo Foundation for Medic...

1. A method for inducing insulin secretion or treating diabetes, wherein said method comprises administering a composition comprising a polypeptide consisting of the sequence set forth in SEQ ID NO:11 to a mammal.
US Pat. No. 10,338,084

PROCESSING REAGENT AND USE THEREOF IN ASSAYS FOR DETECTION OF ANALYTES ASSOCIATED WITH A BINDING PROTEIN

Quidel Corporation, San ...

1. A method to process and assay a sample, comprising:providing a sample suspected of comprising vitamin D or a metabolite of vitamin D each bound to a binding protein;
contacting the sample with a processing reagent comprising between about 0.2 M to about 0.45 M metaperiodate at a ratio of between about 1:2 and 1:12 to form a mixture;
exposing the mixture to a catalyst that is heat or a manganese salt; and
assaying the mixture by performing an immunoassay comprising contacting an aliquot of the mixture with an antibody that specifically binds vitamin D or vitamin D metabolite to detect vitamin D or vitamin D metabolite in the sample, wherein exposing the mixture to a catalyst that is heat comprises incubating the mixture at a temperature above 25° C. and less than 90° C.
US Pat. No. 10,336,036

CEMENTITIOUS ARTICLE COMPRISING HYDROPHOBIC FINISH

United States Gypsum Comp...

1. A mat-faced gypsum board comprising:(a) gypsum-based core;
(b) fibrous mat having (i) an inner surface in direct contact with at least one face of the gypsum-based core and (ii) an opposite outer surface; and
(c) a continuous hydrophobic finish in direct contact with the outer surface of the fibrous mat, the hydrophobic finish prepared from a wet hydrophobic finish composition comprising:
(i) Class C fly ash, wherein the Class C fly ash is in an amount from about 50% to about 85% by weight of the wet hydrophobic finish composition,
(ii) film-forming polymer, wherein the film-forming polymer is in an amount from about 5% to about 25% by weight of the wet hydrophobic finish composition, and
(iii) silane compound of the general chemical formula:
(RO)3—Si—X,
where RO is an alkoxy group and X is an organofunctional group,
wherein the wet hydrophobic finish composition has a pH of at least about 9, and wherein the wet hydrophobic finish composition is substantially free of any other hydraulic material other than the Class C fly ash,
wherein the film-forming polymer is selected from the group consisting of acrylic polymers and copolymers formed from methyl acrylate, methyl methacrylate, ethyl acrylate, ethyl methacrylate, butyl acrylate, butyl methacrylate, propyl acrylate, propyl methylacrylate, 2-ethyl hexyl acrylate and methacrylate, cyclohexyl acrylate and methacrylate, decyl-acrylate and methacrylate, isodecylacrylate and methacrylate, benzyl acrylate and methacrylate, copolymers of styrene and acrylic, copolymers of vinyl acetate and VeoVa (vinyl ester of versatic acid), copolymers of vinyl laurate and ethylene, terpolymers of vinyl acetate, ethylene and methylmethacrylate, terpolymers of vinyl acetate, ethylene and vinyl laurate, terpolymers of vinyl acetate, ethylene and VeoVa (vinyl ester of versatic acid), and any combination thereof,wherein the board passes the test for waterproofness according to ANSI A118.10 (revised October 2008).
US Pat. No. 10,337,060

METHOD FOR CHARACTERISING A DOUBLE STRANDED NUCLEIC ACID USING A NANO-PORE AND ANCHOR MOLECULES AT BOTH ENDS OF SAID NUCLEIC ACID

Oxford Nanopore Technolog...

1. A method of characterising a target double stranded polynucleotide using a transmembrane pore in a membrane, comprising:a) providing the target double stranded polynucleotide with a Y adaptor at one end and a hairpin loop adaptor at the other end, wherein the Y adaptor comprises one or more first anchors for coupling the polynucleotide to the membrane, wherein the hairpin loop adaptor comprises one or more second anchors for coupling the polynucleotide to the membrane and wherein the strength of coupling of the hairpin loop adaptor to the membrane is greater than the strength of coupling of the Y adaptor to the membrane;
b) contacting the polynucleotide provided in step a) with the transmembrane pore such that at least one strand of the polynucleotide moves through the pore; and
c) taking one or more measurements as the at least one strand of the polynucleotide moves with respect to the pore wherein the measurements are indicative of one or more characteristics of the at least one strand of the polynucleotide and thereby characterising the double stranded target polynucleotide.
US Pat. No. 10,336,805

CONSUMABLE CRYOPRESERVED CELLS TRANSIENTLY OVEREXPRESSING GENE(S) ENCODING DRUG TRANSPORTER PROTEIN(S) AND/OR DRUG METABOLIZING ENZYME(S)

Corning Incorporated, Co...

1. A recombinant cell comprising one or more transiently overexpressed genes encoding a drug transporter protein, wherein:the recombinant cell is cryopreserved,
activity of the drug transporter protein is detectable in a population of the recombinant cells prior to cryopreservation,
activity of the drug transporter protein is detectable in a population of the recombinant cells following thaw from cryopreservation;
wherein the cryopreserved recombinant cell is transiently transfected with the one or more genes by a method comprising electroporation; and
wherein said one or more genes is MATE2K and wherein said cell is HEK293.
US Pat. No. 10,336,806

CONSUMABLE CRYOPRESERVED CELLS TRANSIENTLY OVEREXPRESSING GENE(S) ENCODING DRUG TRANSPORTER PROTEIN(S) AND/OR DRUG METABOLIZING ENZYME(S)

Corning Incorporated, Co...

1. A cryopreserved recombinant cell comprising one or more transiently overexpressed genes encoding a drug transporter protein, wherein activity of the drug transporter protein is detectable in a population of the cryopreserved recombinant cells following thaw from cryopreservation, wherein the cryopreserved recombinant cell is transiently transfected with the one or more genes by a method comprising electroporation, and wherein said one or more genes is MATE2K and wherein said cell is HEK293.
US Pat. No. 10,337,062

TRANSPOSITION OF NATIVE CHROMATIN FOR PERSONAL EPIGENOMICS

The Board of Trustees of ...

1. A method for determining accessibility of a site of a polynucleotide to an insertional enzyme complex, comprising:(a) contacting said polynucleotide with an insertional enzyme complex to produce at least one tagged fragment of said polynucleotide;
(b) performing a nucleic acid assay on said at least one tagged fragment or a derivative thereof to provide insertion data; and
(c) analyzing said insertion data to determine accessibility of said site of said polynucleotide to said insertional enzyme complex.
US Pat. No. 10,336,039

RESIN-COMPATIBLE LAMINATE STRUCTURES

EI DU PONT DE NEMOURS AND...

1. A laminate structure suitable for use as electrical insulation, comprising:a) a first paper layer comprising 90 to 99 weight percent uniformly distributed calcined mica and 1 to 10 weight percent supporting material, a majority by weight of the supporting material being in the form of an aramid floc, the supporting material further comprising a binder that is an aramid fibrid; and
b) a support layer comprising unidirectional filaments or unidirectional yarns or woven yarns, the support layer having a first and second face;
wherein the first face of the support layer is directly bound to a face of the first paper layer;
the laminate structure having a dielectric strength of 15 kV/mm or greater, a Gurley porosity of 400 seconds or less, and a total mica content of 60 weight percent or greater,
wherein the floc in the first paper layer is present in an amount of 60 weight percent or greater, based on the total amount of the supporting material in the first paper layer.
US Pat. No. 10,336,807

CHIMERIC PROTEINS AND METHODS OF IMMUNOTHERAPY

The Board of Trustees of ...

1. A method of inducing death of a target cell, comprising:(a) expressing a system in a lymphocyte; and
(b) contacting said target cell with the lymphocyte under conditions that induce said death of the target cell,
wherein the system expressed in the lymphocyte comprises:
(i) a chimeric transmembrane receptor polypeptide (receptor) comprising a ligand binding domain, an immune cell signaling domain, and a gene modulating polypeptide (GMP), wherein the GMP comprises an actuator moiety linked to a cleavage recognition site, wherein the actuator moiety modulates expression and/or activity of an immune regulatory protein of the lymphocyte, and wherein the immune regulatory protein enhances lymphocyte cytotoxicity and/or reduces a side effect of lymphocyte activation; and
(ii) a chimeric adaptor polypeptide (adaptor) comprising a receptor binding moiety linked to a cleavage moiety, wherein the cleavage moiety is capable of cleaving the cleavage recognition site on the receptor when the receptor binding moiety of the adaptor binds the immune cell signaling domain of the receptor in response to binding of the ligand binding domain of the receptor to a ligand present on the target cell, and wherein the adaptor does not bind a ligand present on the target cell;
wherein the receptor is activatable upon binding to the ligand present on the target cell to recruit the adaptor to the receptor in the lymphocyte, and wherein the recruited adaptor releases the actuator moiety from the GMP of the receptor by action of the cleavage moiety at the cleavage site, thereby inducing death of the target cell.
US Pat. No. 10,336,040

METHOD FOR MANUFACTURING A COMPOSITE ELEMENT FOR VACUUM INSULATION ELEMENTS

BASF SE, Ludwigshafen (D...

1. A method for manufacturing a composite element comprising a single- or multi-part core and an envelope which are in a force fit combination with each other, the method comprising:at least partly enveloping a single- or multi-part core of an evacuable organic material with an envelope to obtain a composite element precursor, wherein an envelope surface apposing the core comprises a thermoplastic material;
treating the composite element precursor for a period leading to an at least partial softening of the evacuable organic material and of the envelope surface apposing the core.
US Pat. No. 10,336,808

MHC PEPTIDE COMPLEXES AND USES THEREOF IN INFECTIOUS DISEASES

1. An isolated MHC multimer comprising (a-b-P)n,wherein n>1,
wherein a and b together form a functional MHC protein which is bound to the peptide P,
wherein (a-b-P) is the MHC peptide complex formed when the peptide P is bound to the functional MHC protein,
wherein each MHC peptide complex of the MHC multimer is associated with one or more multimerization domains selected from the group consisting of scaffolds, carriers, optionally substituted organic molecules, membranes, liposomes or micelles, polymers, polysaccharides, dextran moieties, IgG domains, coiled-coil polypeptide structures, DNA duplexes, nucleic acid duplexes, PNA-PNA, PNA-DNA, DNA-RNA, avidins, streptavidins, antibodies, small organic molecules, proteins, a solid support, and biological polymers, with the proviso that the one or more multimerization domains is not a cell,
wherein each MHC protein is an MHC class I molecule encoded by an HLA-A*02 allele, and
wherein in at least one MHC peptide complex, the sequence of P originates from a Borrelia OspC antigen, is capable of binding said MHC class I molecule encoded by an HLA-A*02 allele, and is selected from the group consisting of SEQ ID NOS:49735, 49739, 49779, 49795, 49921, and 49937.
US Pat. No. 10,337,064

METHOD FOR SCREENING AGENTS PROMOTING SKIN BARRIER FUNCTION AND METHOD FOR EVALUATING SKIN BARRIER FUNCTION TAKING EPIDERMAL SERINE RACEMASE AND/OR D-SERINE LEVEL AS INDICATOR

SHISEIDO COMPANY, LTD., ...

1. A method for evaluating a skin barrier function comprising:measuring in a skin sample isolated from a subject an expression level of serine racemase; and
determining the skin barrier function of the subject from the measured expression level of serine racemase.
US Pat. No. 10,336,041

COEXTRUDED MULTILAYER FILM WITH PROPYLENE-BASED POLYMER AND ETHYLENE-BASED POLYMER

Dow Global Technologies L...

1. A coextruded multilayer film comprising:a core component comprising from 15 to 1000 alternating layers of layer A and layer B;
layer A comprising a propylene homopolymer having a density from 0.85 g/cc to 0.95 g/cc and a thickness from 30 nm to 1000 nm and a crystallization temperature (Tpc);
layer B comprising a high density polyethylene (HDPE) having a density of at least 0.94 g/cc and a crystallization temperature (TEc), wherein Tpc is from 115° C. to less than 118° C.; TEc is from greater than 118° C. to 120° C.; and
wherein Tpc layer A has an effective moisture permeability less than 0.40 g-mil/100in2day.
US Pat. No. 10,336,809

PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS

IMMATICS BIOTECHNOLOGIES ...

1. A pharmaceutical composition comprising a peptide consisting of the amino acid sequence SEQ ID NO: 14 in the form of a pharmaceutically acceptable salt; and an immunogenicity enhancing amount of at least one adjuvant.
US Pat. No. 10,337,065

TRNA QUANTIFICATION

THE ROCKEFELLER UNIVERSIT...

1. A method for creating a tRNA profile of a cell, said method comprising:a) removing RNA from said cell,
b) hybridizing said RNA with a plurality of DNA probes specific for a portion of tRNA to form DNA/tRNA hybrids, wherein two DNA probes collectively hybridize to the full length of the tRNA, and wherein said probes each hybridize to at least one ribonucleotide of the anticodon of said tRNA,
c) ligating the DNA of said hybrids,
d) digesting the tRNA from said ligated hybrids to form ligated DNA,
e) sequencing said ligated DNA to obtain sequences that correlate to the tRNA present in the cell, and
f) analyzing said sequences to identify the amount of each tRNA in said cell.
US Pat. No. 10,337,066

METHODS FOR PCR AND HLA TYPING USING UNPURIFIED SAMPLES

Genomics USA, Inc., Roun...

1. A method for amplifying one or more RNAs of interest, comprising:obtaining a sample from an individual;
performing a first reverse transcription reaction on said sample to produce a first cDNA product(s);
diluting the first cDNA product(s) as template into a first PCR reaction; and
performing PCR thereon until all primers are consumed to produce amplicon(s), thereby amplifying the RNA(s) of interest;
wherein the first amplicon(s) are one or more of an HLA-A, an HLA-B or an HLA-DRB1, an HLA-DQA1, or an HLA-DQB1 cDNA(s) and the exon specific primers have a sequence shown in SEQ ID NOS: 15-27.
US Pat. No. 10,337,067

COMPOSITIONS AND METHODS FOR DETERMINING LIKELIHOOD OF TWINNING

Wisconsin Alumni Research...

1. A method for identifying and breeding a member of a bovine population with a decreased likelihood of twinning, comprising the steps of:a) extracting a deoxyribonucleic acid (DNA) sample from a member of the bovine population;
b) detecting, in the DNA sample, the presence of an A allele at nucleotide position 64270644 on bovine chromosome 5 (BTA5), wherein the detecting comprises a laboratory analysis or a field test which utilizes allele-specific polymerase chain reaction (PCR), a nucleic acid probe that specifically binds to the allele, or single-base primer extension;
c) identifying said member of the bovine population as a member of the bovine population with decreased likelihood of twinning; and
d) breeding said member of the bovine population with another bovine animal.
US Pat. No. 10,336,812

GDF15 FUSION PROTEINS AND USES THEREOF

Janssen Biotech, Inc., H...

1. A fusion protein comprising:a. the amino acid sequence of SEQ ID NO: 2;
b. a linker having a length of 35-48 amino acids and comprising the amino acid sequence of (GGGGS)n, wherein n is 7 or 8 (SEQ ID NO: 42 or 43); and
c. a truncated GDF15 consisting of the amino acid sequence of SEQ ID NO: 8;
wherein the fusion protein is arranged from N-terminus to C-terminus in the order (a)-(b)-(c), and the C-terminus of the amino acid sequence of SEQ ID NO: 2 is fused to the N-terminus of the truncated GDF15 through the linker.
US Pat. No. 10,337,068

TRPC6 INVOLVED IN GLOMERULONEPHRITIS

DUKE UNIVERSITY, Durham,...

1. A method of detecting a mutation in a human Transient Receptor Potential Cation Channel, Subfamily C, Member 6 (TRPC6) gene in a sample from a human individual, comprising:(a) contacting a sample comprising a TRPC6 polynucleotide from a human with an oligonucleotide probe, wherein the probe specifically binds to a portion of the nucleotide sequence of SEQ ID NO: 64 including position 762 of the nucleotide sequence of SEQ ID NO: 64, and wherein the probe is detectably labeled with a moiety selected from the group consisting of: enzymatic, radioactive, fluorescent, and luminescent moieties;
(b) hybridizing the probe to the TRPC6 polynucleotide; and
(c) detecting hybridization of the probe to the TRPC6 polynucleotide, wherein hybridization is indicative of the presence of a mutation in the TRPC6 gene in the sample.
US Pat. No. 10,336,045

MATTE FINISH POLYIMIDE FILMS AND METHODS RELATING THERETO

E I DU PONT DE NEMOURS AN...

1. A base film comprising:A. a chemically converted polyimide present in an amount from 75 to 96 weight percent of the base film, the chemically converted polyimide being derived from:
a. 100 mole percent pyromellitic dianhydride, based upon a total dianhydride content of the chemically converted polyimide;
b. 20-80 mole percent 4,4?-oxydianiline based upon a total diamine content of the chemically converted polyimide; and
c. 80-20 mole percent p-phenylenediamine based upon the total diamine content of the chemically converted polyimide;
B. a low conductivity carbon black present in an amount from 2 to 9 weight percent of the base film; and
C. a particulate polyimide matting agent present in an amount from 1.6 to 9 weight percent of the base film and having a median particle size from 1.3 to 10 microns.
US Pat. No. 10,336,813

FUSION PROTEIN SLIT2D2-HSA AND ITS USE IN TREATMENT OF SEPSIS

ASCLEPIUS (SUZHOU) TECHNO...

1. A fusion protein Slit2D2-HSA formed by the fusion of a D2 domain of Slit2 protein and a HSA protein;wherein said D2 domain of Slit2 comprises:
a) an amino acid sequence shown by SEQ ID NO: 1, or
b) an amino acid sequence with a same function obtained by substitution and/or deletion and/or addition of one or more amino acid residues of the aforesaid sequence a);
said HSA comprises:
c) an amino acid sequence shown by SEQ ID NO: 2, or
d) an amino acid sequence with a same function obtained by substitution and/or deletion and/or addition of one or more amino acid residues of the aforesaid sequence c);
wherein the C-terminal domain of said D2 domain of Slit2 is directly linked to the N-terminal domain of said HSA protein, or the N-terminal domain of said D2 domain of Slit2 is directly linked to the C-terminal domain of said HSA protein; and wherein up to 10 amino acid residues are changed for substitution and/or deletion and/or addition.
US Pat. No. 10,337,070

METHODS AND KITS FOR TREATING CARDIOVASCULAR DISEASE

CardioForecast Ltd., Lon...

1. A method of treating a human subject at risk of a future cardiac event comprising:(a) obtaining information regarding the human subject's single nucleotide polymorphism (SNP) alleles for each of the rs16944 polymorphic locus, the rs1143623 polymorphic locus, the rs4848306 polymorphic locus, the rs17561 polymorphic locus, and the rs1143634 polymorphic locus;
(b) determining that the subject has a positive IL-1 genotype pattern when the IL-1 genotype pattern obtained in (a) matches an IL-1 genotype pattern that is selected from the group consisting of:
(i) T/T or T/G at rs17561, C/C, T/T, C/T or T/C at rs4848306, G/G at rs1143623, C/C at rs16944 and T/T or T/C at rs1143634;
(ii) G/G at rs17561, C/C, T/T, C/T or T/C at rs4848306, G/G at rs1143623, C/C at rs16944 and C/C, T/T, C/T or T/C at rs1143634;
(iii) G/G, T/T, G/T or T/G at rs17561, C/C, T/T, C/T or T/C at rs4848306, G/G at rs1143623, C/C at rs16944 and C/C at rs1143634;
(iv) T/T or T/G at rs17561, C/C or C/T at rs4848306, G/G at rs1143623, C/T at rs16944 and T/T or T/C at rs1143634;
(v) G/G at rs17561, C/C or C/T at rs4848306, G/G at rs1143623, C/T at rs16944 and C/C, T/T, C/T or T/C at rs1143634;
(vi) G/G, T/T, G/T or T/G at rs17561, C/C or C/T at rs4848306, G/G at rs1143623, C/T at rs16944 and C/C at rs1143634;
(vii) T/T or T/G at rs17561, C/C at rs4848306, C/G at rs1143623, C/T at rs16944 and T/T or T/C at rs1143634; 2
(viii) G/G at rs17561, C/C at rs4848306, C/G at rs1143623, C/T at rs16944 and C/C, T/T, C/T or T/C at rs1143634;
(ix) G/G, T/T, G/T or T/G at rs17561, C/C at rs4848306, C/G at rs1143623, C/T at rs16944 and C/C at rs1143634;
(x) T/T or T/G at rs17561, C/C at rs4848306, G/G at rs1143623, T/T at rs16944 and T/T or T/C at rs1143634;
(xi) G/G at rs17561, C/C at rs4848306, G/G at rs1143623, T/T at rs16944 and C/C, T/T, C/T or T/C at rs1143634; and
(xii) G/G, T/T, G/T or T/G at rs17561, C/C at rs4848306, G/G at rs1143623, T/T at rs16944 and C/C at rs1143634;
(c) determining at least one of:
(i) a plasma concentration of LDL-C; and/or
(ii) a plasma concentration of Lp(a)in a sample obtained from the subject;(d) diagnosing the subject as at risk of a cardiac event when the subject has a positive IL-1 pattern determined in step (b) and
(i) a total LDL-C plasma concentration of at least 50 mg/dL, and/or
(ii) a total Lp(a) plasma concentration of at least 5 mg/dL; and
(e) administering canakinumab to the diagnosed subject, thereby reducing the probability of a cardiac event in the subject.
US Pat. No. 10,339,377

DEVICE AND METHOD FOR DETERMINING CHARACTERISTICS OF A CURRENCY NOTE

Kabushiki Kaisha Toshiba,...

1. A method for determining one or more characteristics of a currency note, comprising:receiving, by a currency evaluating device, an image of a currency note;
detecting, by the currency evaluating device, text from one or more predefined first regions of the image;
identifying, by the currency evaluating device, language associated with the detected text;
obtaining, by the currency evaluating device, one of a single nationality or a plurality of nationalities associated with the language of the currency note from a data source associated with the currency evaluating device;
identifying, by the currency evaluating device, nationality of the currency note as said single nationality, when the single nationality is obtained;
identifying, by the currency evaluating device, nationality of the currency note from the plurality of nationalities using Optical Character Recognition (OCR), when the plurality of nationalities is obtained; and
determining, by the currency evaluating device, the one or more characteristics of the currency note by extracting object features of the image based on the identified nationality.
US Pat. No. 10,336,816

PHAGE-DISPLAYED SINGLE-CHAIN VARIABLE FRAGMENT LIBRARY

Academia Sinica, Taipei ...

1. A phage-displayed single-chain variable fragment (scFv) library comprising a plurality of phage-displayed scFvs, wherein each of the plurality of phage-displayed scFvs comprises a first heavy chain complementarity determining region (CDR-H1), a second heavy chain CDR (CDR-H2), a third heavy chain CDR (CDR-H3), a first light chain CDR (CDR-L1), a second light chain CDR (CDR-L2), and a third light chain CDR (CDR-L3),wherein,
each of the CDR-H1, CDR-L2 and CDR-L3 has a type 1 canonical structure (CS), whereas each of the CDR-H2 and CDR-L1 has a type 2 CS; and
each of the CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 has a distribution of aromatic residues that is similar to the distribution of aromatic residues in the corresponding CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 of a natural antibody; wherein
the CDR-L1 is encoded by a first coding sequence comprising the nucleic acid sequence of any of SEQ ID NOs: 2-10, the CDR-L2 is encoded by a second coding sequence comprising the nucleic acid sequence of any of SEQ ID NOs: 11-14, the CDR-L3 is encoded by a third coding sequence comprising the nucleic acid sequence of any of SEQ ID NOs: 15-22, the CDR-H1 is encoded by a fourth coding sequence comprising the nucleic acid sequence of any of SEQ ID NOs: 23-26, the CDR-H2 is encoded by a fifth coding sequence comprising the nucleic acid sequence of any of SEQ ID NOs: 27-28, and the CDR-H3 is encoded by a sixth coding sequence comprising the nucleic acid sequence of any of SEQ ID NOs: 29-106.
US Pat. No. 10,337,072

COPY NUMBER DETECTION AND METHODS

The Board of Trustees of ...

1. A method of determining copy number of a variable copy number version of a replicated target nucleic acid sequence in a sample from a plant, comprising:contacting a sample comprising single-stranded genomic nucleic acids with:
(1) a pair of oligonucleotide primers that anneal upstream and downstream, respectively, of a sequence within the both the defined copy number version and the variable copy number versions of replicated target nucleic acid sequence;
(2) a first non-extendable oligonucleotide probe, with a first 5? fluorescent reporter label and an internal or 3? quencher dye, which first probe anneals specifically to the defined copy number version of the replicated target sequence between the pair of oligonucleotide primers; and
(3) a second non-extendable oligonucleotide probe, with a second 5? fluorescent reporter label and an internal or 3? quencher dye, which second probe anneals specifically to the variable copy number version of the replicated target sequence between the pair of oligonucleotide primers to produce a mixture,wherein the defined copy number version and the variable copy number versions of the target nucleic acid are in the same genome and wherein the defined copy number version of the replicated target nucleic acid sequence is a homeolog of the variable copy number version;maintaining the mixture with a template-dependent nucleic acid polymerase having a 5? to 3? nuclease activity under conditions sufficient to permit the 5? to 3? nuclease activity of the polymerase to cleave the annealed probes and release labeled fragments;
measuring the release of nucleic acid fragments containing fluorescent report label; and
determining the relative amount of released first and second fluorescent reporter fragments, thereby determining copy number of the variable copy number version of the replicated target nucleic acid sequence.
US Pat. No. 10,336,817

THERAPEUTIC COMPOSITION OF CAMEL MILK

Sultan Qaboos University,...

1. A method of making a therapeutic composition of camel milk, comprising the steps of:immunizing a camel against HIV with DNA encoding HIV antigens to provide an HIV-immunized camel, the immunizing comprising 6 immunization treatments, each immunization treatment including administering about 10 mg of DNA encoding HIV antigens to the camel;
preparing an herbal extract comprising the steps of preparing a powdered mixture of the solid material of Saussurea acrophila Diels, Saussurea ceratocarpa, and Aucklandia lappa Decne, soaking the powdered mixture in a first solvent to provide a solvent/powder mixture, incubating the powder/mixture at room temperature, filtering the powder/mixture after incubation to provide a first filtrate and a first retentate, allowing the first solvent to evaporate from the first filtrate, and combining the first filtrate with a second solvent to provide a re-extraction mixture, filtering the re-extraction mixture to provide an extract solution and a second retentate, and allowing the second solvent to evaporate from the extract solution to provide the herbal extract, the herbal extract comprising about 14% extract of Saussurea acrophila Diels, about 14% extract of Saussurea ceratocarpa, and about 72% extract of Aucklandia lappa Decne;
intubating the HIV-immunized camel with the herbal extract in an amount of 500 g to 800 g of the herbal extract per day; and
then collecting an HIV-immunized camel milk from the immunized camel intubated with the herbal extract, the HIV-immunized camel milk including anti-HIV heavy chain IgG antibodies, the HIV-immunized camel milk providing the therapeutic composition.
US Pat. No. 10,336,818

FC VARIANTS WITH ALTERED BINDING TO FCRN

Xencor, Inc., Monrovia, ...

1. A method of producing a polypeptide comprising a variant Fc region as compared to a parent Fc region, said variant Fc region comprising amino acid substitutions M428L/N434S wherein numbering is according to the EU Index in Kabat et al., said method comprising providing a cell comprising a nucleic acid encoding said polypeptide, wherein said cell is cultured under conditions suitable for expression of said polypeptide.
US Pat. No. 10,336,819

ANTI-TAU ANTIBODIES AND METHODS OF USE

Genentech, Inc., South S...

1. A method of treating a Tau protein associated disease comprising administering to an individual with the Tau protein associated disease a monoclonal antibody that binds to human Tau, wherein the antibody comprises:a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 342; HVR-H2 comprising the amino acid sequence of SEQ ID NO: 343; HVR-H3 comprising the amino acid sequence of SEQ ID NO: 344; HVR-L1 comprising an amino acid sequence selected from SEQ ID NOs: 345, 15, 468 to 478, 495 to 517, 522 to 534, 536 to 539, and 543 to 556; HVR-L2 comprising the amino acid sequence of SEQ ID NO: 346; and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 347;
b) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 72; HVR-H2 comprising the amino acid sequence of SEQ ID NO: 73; HVR-H3 comprising the amino acid sequence of SEQ ID NO: 74; HVR-L1 comprising the amino acid sequence of SEQ ID NO: 75; HVR-L2 comprising the amino acid sequence of SEQ ID NO: 76; and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 77;
c) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 42; HVR-H2 comprising the amino acid sequence of SEQ ID NO: 43; HVR-H3 comprising the amino acid sequence of SEQ ID NO: 44; HVR-L1 comprising the amino acid sequence of SEQ ID NO: 45; HVR-L2 comprising the amino acid sequence of SEQ ID NO: 46; and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 47;
d) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 62; HVR-H2 comprising the amino acid sequence of SEQ ID NO: 63; HVR-H3 comprising the amino acid sequence of SEQ ID NO: 64; HVR-L1 comprising the amino acid sequence of SEQ ID NO: 65; HVR-L2 comprising the amino acid sequence of SEQ ID NO: 66; and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 67;
e) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 212; HVR-H2 comprising the amino acid sequence of SEQ ID NO: 213; HVR-H3 comprising the amino acid sequence of SEQ ID NO: 214; HVR-L1 comprising the amino acid sequence of SEQ ID NO: 215; HVR-L2 comprising the amino acid sequence of SEQ ID NO: 216; and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 217;
f) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 32; HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; HVR-H3 comprising the amino acid sequence of SEQ ID NO: 34; HVR-L1 comprising the amino acid sequence of SEQ ID NO: 35; HVR-L2 comprising the amino acid sequence of SEQ ID NO: 36; and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 37; or
g) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 52; HVR-H2 comprising the amino acid sequence of SEQ ID NO: 53; HVR-H3 comprising the amino acid sequence of SEQ ID NO: 54; HVR-L1 comprising the amino acid sequence of SEQ ID NO: 55; HVR-L2 comprising the amino acid sequence of SEQ ID NO: 56; and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 57.
US Pat. No. 10,336,820

ANTIBODIES DIRECTED TO ANGIOPOIETIN-1 AND ANGIOPOIETIN-2 AND USES THEREOF

Amgen Inc., Thousand Oak...

1. A method of treating a solid tumor in a subject, comprising administering to the subject an effective amount of an isolated monoclonal antibody to inhibit tumor-associated neovascularization, wherein said antibody comprises a heavy chain variable domain and a light chain variable domain, wherein said heavy chain comprises 3 CDRs and said light chain comprises 3 CDRs, wherein the sequences of said CDRs of said antibody are selected from the group consisting of:(a) SEQ ID NOs: 18, 26, 32 of the HC plus SEQ ID NOs: 19, 27, 33 of the LC,
(b) SEQ ID NOs: 18, 26, 34 of the HC plus SEQ ID NOs: 19, 27, 33 of the LC,
(c) SEQ ID NOs: 18, 26, 35 of the HC plus SEQ ID NOs: 20, 27, 36 of the LC,
(d) SEQ ID NOs: 18, 26, 37 of the HC plus SEQ ID NOs: 19, 27, 33 of the LC,
(e) SEQ ID NOs: 18, 26, 38 of the HC plus SEQ ID NOs: 19, 27, 33 of the LC,
(f) SEQ ID NOs: 18, 26, 35 of the HC plus SEQ ID NOs: 19, 27, 33 of the LC,
(g) SEQ ID NOs: 18, 26, 34 of the HC plus SEQ ID NOs: 21, 27, 33 of the LC,
(h) SEQ ID NOs: 18, 28, 39 of the HC plus SEQ ID NOs: 19, 27, 33 of the LC,
(i) SEQ ID NOs: 18, 26, 34 of the HC plus SEQ ID NOs: 22, 27, 33 of the LC,
(j) SEQ ID NOs: 18, 26, 32 of the HC plus SEQ ID NOs: 22, 27, 33 of the LC,
(k) SEQ ID NOs: 18, 29, 39 of the HC plus SEQ ID NOs: 19, 27, 33 of the LC,
(l) SEQ ID NOs: 18, 26, 34 of the HC plus SEQ ID NOs: 23, 27, 33 of the LC,
(m) SEQ ID NOs: 18, 26, 35 of the HC plus SEQ ID NOs: 20, 27, 40 of the LC,
(n) SEQ ID NOs: 18, 26, 32 of the HC plus SEQ ID NOs: 21, 27, 33 of the LC,
(o) SEQ ID NOs: 18, 26, 35 of the HC plus SEQ ID NOs: 24, 27, 33 of the LC,
(p) SEQ ID NOs: 18, 26, 35 of the HC plus SEQ ID NOs: 21, 27, 33 of the LC,
(q) SEQ ID NOs: 18, 26, 35 of the HC plus SEQ ID NOs: 23, 27, 33 of the LC,
(r) SEQ ID NOs: 18, 26, 34 of the HC plus SEQ ID NOs: 20, 30, 33 of the LC,
(s) SEQ ID NOs: 18, 26, 34 of the HC plus SEQ ID NOs: 25, 27, 33 of the LC,
(t) SEQ ID NOs: 18, 26, 35 of the HC plus SEQ ID NOs: 20, 30, 33 of the LC,
(u) SEQ ID NOs: 18, 26, 34 of the HC plus SEQ ID NOs: 20, 27, 40 of the LC, and
(v) SEQ ID NOs: 18, 26, 34 of the HC plus SEQ ID NOs: 20, 31, 33 of the LC;wherein said antibody specifically binds to at least one of Angiopoietins-1 (Ang-1) and Angiopoetin-2 (Ang-2) ligands of Tie 2 receptor tyrosine kinase.
US Pat. No. 10,336,822

EARLY MARKER OF PROTEINURIA IN PATIENTS TREATED WITH AN ANTI-VEGF TREATMENT

Mayo Foundation for Medic...

1. A method for treating a human having cancer, wherein said method comprises:(a) administering an original dose of an anti-VEGF therapy to said human to treat said cancer, and
(b) administering a subsequent dose of said anti-VEGF therapy to said human, wherein said human, following administration of said original dose, was identified as having a urine sample that lacks podocytes or polypeptides expressed by podocytes, wherein said subsequent dose is the same amount as said original dose.
US Pat. No. 10,334,772

GROWTH ENHANCEMENT OF PLANT

RHODIA OPERATIONS, Paris...

18. A seed coated by at least one cationic galactomannan selected from the group consisting of: cationic fenugreek gum, cationic tara gum, cationic locust bean gum, and cationic cassia gum, wherein the at least one cationic compound has an average Molecular Weight of from about 20,000 Daltons to 20,000,000 Daltons.
US Pat. No. 10,336,823

ANTI-B7-H1 ANTIBODIES FOR TREATING TUMORS

MedImmune Limited, Cambr...

1. A method of treating a patient identified as having non-small cell lung carcinoma (NSCLC), the method comprising administering to the patient 10 mg/kg of an isolated antibody or an antigen-binding fragment thereof that specifically binds to PD-L1, the isolated antibody or fragment thereof comprising:a VH CDR1 having the amino acid sequence of SEQ ID NO: 3;
a VH CDR2 having the amino acid sequence of SEQ ID NO: 4;
a VH CDR3 having the amino acid sequence of SEQ ID NO: 5;
a VL CDR1 having the amino acid sequence of SEQ ID NO: 6;
a VL CDR2 having the amino acid sequence of SEQ ID NO: 7; and
a VL CDR3 having the amino acid sequence of SEQ ID NO: 8,wherein at least 25% of the NSCLC tumor cells are PD-L1 positive.
US Pat. No. 10,337,079

MARAGING STEEL

DAIDO STEEL CO., LTD., N...

1. A maraging steel consisting of:as essential components,
0.20 mass %?C5.1?0.35 mass %,
9.0 mass %?Co?20.0 mass %,
1.0 mass %?(Mo+W/2)?2.0 mass %,
1.0 mass %?Cr?4.0 mass %, and
a certain amount of Ni, and
as optional components,
Al?0.10 mass %,
Ti?0.10 mass %,
S?0.0010 mass %,
N?0.0020 mass %,
V+Nb?0.60 mass %,
B?0.0050 mass %, and
Si?1.0 mass %,
with a balance being Fe and inevitable impurities,
wherein, in a case where contents of V and Nb satisfy V+Nb?0.020 mass %, an amount of Ni is:
6.0 mass %?Ni?9.4 mass %, and
wherein, in a case where the contents of V and Nb satisfy0.020 mass %
US Pat. No. 10,336,824

ANTI-PDL1 ANTIBODIES, ACTIVATABLE ANTI-PDL1 ANTIBODIES, AND METHODS OF THEREOF

CytomX Therapeutics, Inc....

1. An isolated antibody or antigen binding fragment thereof (AB) wherein the AB comprises:(a) a heavy chain variable region (VH) comprising:
i. a variable heavy chain complementarity determining region 1 (VH CDR1) comprising the amino acid sequence of SEQ ID NO: 2.12;
ii. a variable heavy chain complementarity determining region 2 (VH CDR2) comprising the amino acid sequence of SEQ ID NO: 246;
iii. a variable heavy chain complementarity determining region 3 (VH CDR3) comprising the amino acid sequence of SEQ ID NO: 235; and
(b) a light chain variable region (VL) comprising:
i. a variable light chain complementarity determining region 1 (VL CDR1) comprising the amino acid sequence of SEQ ID NO: 209;
ii. a variable light chain complementarity determining region 2 (VL CDR2) comprising an amino acid sequence of SEQ ID NOs: 215 or 227; and
iii. a variable light chain complementarity determining region 3 (VL CDR3) comprising the amino acid sequence of SEQ ID NO: 228,
wherein the AB specifically binds mammalian PDL1.
US Pat. No. 10,336,825

ANTIBODY BINDING TO FCRN FOR TREATING AUTOIMMUNE DISEASES

HANALL BIOPHARMA CO., LTD...

1. An isolated anti-FcRn antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region comprising CDR1 comprising an amino acid sequence of SEQ ID No: 27, CDR2 comprising an amino acid sequence of SEQ ID No: 28, and CDR3 comprising an amino acid sequence of SEQ ID No: 29; and a light chain variable region comprising CDR1 comprising an amino acid sequence of SEQ ID No: 30, CDR2 comprising an amino acid sequence of SEQ ID No: 31, and CDR3 comprising an amino acid sequence of SEQ ID No: 32,wherein the antibody or antigen-binding fragment binds to an epitope of human FcRn comprising residues S15, S16, P17, P19, G20, A23, F24, S40, L41, R42, R69, E72, K73, F75, L76, F79, G84 and Y88 of ? chain extracellular domain (SEQ ID NO:45) and E36 of ?2m chain (SEQ ID NO:46).
US Pat. No. 10,336,826

ANTIBODIES TO VLA-1

Biogen MA Inc., Cambridg...

1. A method of treating a subject having psoriasis, comprising administering to the subject a composition comprising an anti-VLA-1 antibody or antigen binding fragment thereof, and a pharmaceutically acceptable carrier, wherein the antibody or antigen binding fragment thereof comprises light chain complementarity determining regions defined by amino acid residues 24 to 33, 49 to 55 and 88 to 96 of SEQ ID NO:1, and heavy chain complementarity determining regions defined by amino acid residues 31 to 35, 50 to 65 and 98 to 107 of SEQ ID NO:2.
US Pat. No. 10,336,827

COMPOSITIONS AND METHODS TO TREAT SOLID TUMORS

Wayne State University, ...

1. A method of inducing apoptosis of cells of an ovarian tumor in a subject in need thereof comprising administering a therapeutically effective amount of an anti-CD11b antibody and/or Abciximab to the subject, thereby inducing apoptosis of cells of the ovarian cancer solid tumor in the subject.
US Pat. No. 10,337,085

DIE CASTING ALUMINUM ALLOY AND PRODUCTION METHOD THEREOF, AND COMMUNICATIONS PRODUCT

Huawei Technologies Co., ...

1. A die casting aluminum alloy consisting of the following components in percentage by mass:13.5% to 14.0% of silicon;
0.1% to 0.9% of manganese;
0.1% to 1.0% of magnesium;
0.3% to 1.4% of iron; and
less than or equal to 0.2% of copper and greater than 0% copper, and
a balance being aluminum and inevitable impurities.
US Pat. No. 10,336,830

ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF

HOFFMANN-LA ROCHE INC., ...

1. An isolated nucleic acid encoding an antibody binding to CSF-1R, wherein the antibody comprises a heavy chain variable domain and a light chain variable domain, and wherein:a) the heavy chain variable domain comprises a CDR3 region of SEQ ID NO: 1, a CDR2 region of SEQ ID NO: 2, and a CDR1 region of SEQ ID NO: 3, and the light chain variable domain comprises a CDR3 region of SEQ ID NO: 4, a CDR2 region of SEQ ID NO:5, and a CDR1 region of SEQ ID NO:6, or
b) the heavy chain variable domain comprises a CDR3 region of SEQ ID NO: 9, a CDR2 region of SEQ ID NO: 10, and a CDR1 region of SEQ ID NO: 11, and the light chain variable domain comprises a CDR3 region of SEQ ID NO: 12, a CDR2 region of SEQ ID NO: 13, and a CDR1 region of SEQ ID NO: 14.
US Pat. No. 10,337,086

CORRODIBLE DOWNHOLE ARTICLE

Magnesium Elektron Limite...

1. A corrodible downhole article comprising a magnesium alloy which comprises0.4-10 wt % of a corrosion promoting element Ni,
2-8 wt % Y,
0.1-15 wt % of at least one rare earth metal other than Y, and
0-1 wt % Zr,
wherein a balance is magnesium and incidental impurities,
wherein the corrodible downhole article has a corrosion rate of at least 643 mg/cm2/day in 15% KCl at 93° C. and a 0.2% proof strength of at least 50 MPa when tested using standard tensile test method ASTM B557-10.
US Pat. No. 10,336,831

USE OF ANTI-ENDOGLIN ANTIBODIES FOR TREATING OCULAR FIBROSIS

Tracon Pharmaceuticals, I...

1. A method of treating or inhibiting an ocular fibrosis in a subject in need thereof, comprising administering to the subject an antibody, or antigen-binding fragment thereof, that specifically binds to endoglin; whereby the ocular fibrosis is treated or inhibited.
US Pat. No. 10,336,832

METHODS OF INHIBITING PLASMA KALLIKREIN IN EDEMA PATIENT

Dyax Corp., Lexington, M...

1. A method of inhibiting plasma kallikrein in a subject, the method comprising:administering to a subject in need thereof an antibody that binds to the active form of human plasma kallikrein and does not bind human prekallikrein;
wherein the subject has edema; and wherein the antibody comprises a heavy chain immunoglobulin variable domain sequence comprising three complementarity determining regions (CDRs) from the heavy chain variable domain of an antibody selected from the group consisting of: M162-A04, M160-G12, M142-H08, X63-G06, X101-A01, X81-B01, X67-D03, X67-G04, X115-B07, X115-D05, X115-E09, X115-H06, X115-A03, X115-D01, X115-G04, M29-D09, M145-D11, M06-D09, M76-D01, and M35-G04, and a light chain immunoglobulin variable domain sequence comprising three CDRs from the light chain variable domain of the selected antibody.
US Pat. No. 10,336,833

CONJUGATED ANTI-CD38 ANTIBODIES

Takeda Pharmaceutical Com...

1. An isolated antibody that specifically binds human CD38 (SEQ ID NO:1) and cynomolgus CD38 (SEQ ID NO:2) comprising:a) a heavy chain variable region comprising:
i) a first CDR comprising SEQ ID NO:3;
ii) a second CDR comprising SEQ ID NO:4;
iii) a third CDR comprising SEQ ID NO:5; and
b) a light chain variable region comprising:
i) a first CDR comprising SEQ ID NO:6;
ii) a second CDR comprising SEQ ID NO:7;
iii) a third CDR comprising SEQ ID NO:8; and
c) a covalently attached drug moiety,wherein the heavy chain variable region comprises an amino acid sequence having an identity of at least 90% to SEQ ID NO:9 and the light chain variable region comprises an amino acid sequence having an identity of at least 90% to SEQ ID NO:10.
US Pat. No. 10,336,834

METHODS OF USING ANTI-PHOSPHOLIPASE D4 ANTIBODIES

SBI Biotech Co., Ltd., T...

1. A method for suppressing an activity of a plasmacytoid dendritic cell in a living organism, comprising administering to the living organism an antibody, or antigen-binding fragment thereof, that binds to human phospholipase D4 (PLD4) protein on the plasmacytoid dendritic cell and suppresses the activity of the plasmacytoid dendritic cell, wherein the activity of the plasmacytoid dendritic cell is production of interferon, survival, or production of interferon and survival, and wherein the antibody or antigen-binding fragment thereof comprises:a heavy chain variable region comprising a heavy chain CDR1 set forth in SEQ ID NO:2, a heavy chain CDR2 set forth in SEQ ID NO:3, and a heavy chain CDR3 set forth in SEQ ID NO:4, and a light chain variable region comprising a light chain CDR1 set forth in SEQ ID NO:5, a light chain CDR2 set forth in SEQ ID NO:6, and a light chain CDR3 set forth in SEQ ID NO:7;
a heavy chain variable region comprising a heavy chain CDR1 set forth in SEQ ID NO:8, a heavy chain CDR2 set forth in SEQ ID NO:9, and a heavy chain CDR3 set forth in SEQ ID NO:10, and a light chain variable region comprising a light chain CDR1 set forth in SEQ ID NO:11, a light chain CDR2 set forth in SEQ ID NO:12, and a light chain CDR3 set forth in SEQ ID NO:13;
a heavy chain variable region comprising a heavy chain CDR1 set forth in SEQ ID NO:14, a heavy chain CDR2 set forth in SEQ ID NO:15, and a heavy chain CDR3 set forth in SEQ ID NO:16, and a light chain variable region comprising a light chain CDR1 set forth in SEQ ID NO:17, a light chain CDR2 set forth in SEQ ID NO:18, and a light chain CDR3 set forth in SEQ ID NO:19;
a heavy chain variable region comprising a heavy chain CDR1 set forth in SEQ ID NO:20, a heavy chain CDR2 set forth in SEQ ID NO:21, and a heavy chain CDR3 set forth in SEQ ID NO:22, and a light chain variable region comprising a light chain CDR1 set forth in SEQ ID NO:23, a light chain CDR2 set forth in SEQ ID NO:24, and a light chain CDR3 set forth in SEQ ID NO:25;
a heavy chain variable region comprising a heavy chain CDR1 set forth in SEQ ID NO:26, a heavy chain CDR2 set forth in SEQ ID NO:27, and a heavy chain CDR3 set forth in SEQ ID NO:28, and a light chain variable region comprising a light chain CDR1 set forth in SEQ ID NO:29, a light chain CDR2 set forth in SEQ ID NO:30, and a light chain CDR3 set forth in SEQ ID NO:31;
a heavy chain variable region comprising a heavy chain CDR1 set forth in SEQ ID NO:32, a heavy chain CDR2 set forth in SEQ ID NO:33, and a heavy chain CDR3 set forth in SEQ ID NO:34, and a light chain variable region comprising a light chain CDR1 set forth in SEQ ID NO:35, a light chain CDR2 set forth in SEQ ID NO:36, and a light chain CDR3 set forth in SEQ ID NO:37; or
a heavy chain variable region comprising a heavy chain CDR1 set forth in SEQ ID NO:38, a heavy chain CDR2 set forth in SEQ ID NO:39, and a heavy chain CDR3 set forth in SEQ ID NO:40, and a light chain variable region comprising a light chain CDR1 set forth in SEQ ID NO:41, a light chain CDR2 set forth in SEQ ID NO:42, and a light chain CDR3 set forth in SEQ ID NO:43.
US Pat. No. 10,336,835

POLYMORPHS OF SUGAMMADEX AND PROCESS FOR PREPARATION OF SUGAMMADEX

FORMOSA LABORATORIES, INC...

1. A crystalline form of Suagmmadex sodium, characterized by an X-ray powder diffraction pattern having peaks at 6.7, 17.6, 7.2, 20.8 and 21.4 degrees 2-theta±0.2 degrees 2-theta.
US Pat. No. 10,337,091

HIGH HEAT RESISTANT STEEL WITH LOW NICKEL

Hyundai Motor Company, S...

1. A high heat resistant steel having enhanced castability consisting of:C from about 0.5 to 0.7 wt %,
Si from about 1.3 to 1.7 wt %,
Mn from about 0.6 to 1.0 wt %,
Ni from about 24.0 to 26.0 wt %,
Cr from about 18.0 to 20.0 wt %,
Nb from about 1.0 to 2.0 wt %,
N from about 0.15 to 0.20 wt %, and
the remainder of iron (Fe), and inevitable impurities, based on a total weight of the high heat resistant steel,
wherein a value of X/Y is 0.44 to 0.47;
the X is a value calculated by Equation 1;
X=Cr (wt %)+1.5×Si (wt %)+0.5×Nb (wt %)  [Equation 1]
the Y is a value calculated by Equation 2;
Y=Ni (wt %+0.5×Mn (wt %)+30×C (wt %)+30×N (wt %),  [Equation 2]
wherein the steel has 190 MPa or more of tensile strength at 900° C.
US Pat. No. 10,336,837

PROCESS FOR PRODUCING OLEFIN POLYMER AND OLEFIN POLYMER

MITSUI CHEMICALS, INC., ...

1. A 1-butene polymer which has a meso pentad fraction as measured by 13C-NMR of 98.0% to 99.8%, has a melting point (Tm) of 120 to 150° C., and has a molecular weight distribution (Mw/Mn) of 1.5 to 2.75.
US Pat. No. 10,337,094

HOT-DIP GALVANIZED STEEL SHEET AND PRODUCTION METHOD THEREFOR

JFE Steel Corporation, T...

1. A hot-dip galvanized steel sheet comprising a steel sheet having a composition containing 0.100% to 0.200% C, 0.50% or less Si, 0.60% or less Mn, 0.100% or less P, 0.0100% or less S, 0.010% to 0.100% Al, and 0.0100% or less N on a mass basis, the remainder comprising Fe and inevitable impurities, the steel sheet having a microstructure containing a ferrite phase having an area fraction of 60% to 79%, a pearlite phase having an area fraction of 20% to 30%, and a bainite phase having an area fraction of 1% to 5%, the area fraction of a cementite phase present in a grain of the ferrite phase being 1% or more and 5% or less, wherein the hot-dip galvanized steel sheet has an elongation of 35.6% or more, a tensile strength of 440 MPa to 490 MPa, and a stretch flangeability of 77% or more.
US Pat. No. 10,336,839

FARNESENE-BASED POLYMERS AND LIQUID OPTICALLY CLEAR ADHESIVE COMPOSITIONS INCORPORATING THE SAME

FINA TECHNOLOGY, INC., H...

1. A laminated screen assembly comprising a transparent layer adhered to a display and a cured adhesive between the transparent layer and the display, wherein the cured adhesive is obtained by curing a liquid optically clear adhesive composition comprising a polymer derived from monomers comprising farnesene, the polymer being obtained from a diol prepared by anionically polymerizing monomers comprising farnesene to provide an intermediate polymer having two living ends, quenching the two living ends by reacting the two living ends with an alkylene oxide and a protic source, and hydrogenating the diol, wherein hydroxyl groups of the diol have been further reacted to provide terminal ends functionalized with (meth)acrylate groups and wherein the polymer has a degree of unsaturation less than or equal to 50%.
US Pat. No. 10,336,843

ULTRA-HIGH MOLECULAR WEIGHT ETHYLENE-BASED COPOLYMER POWDER, AND MOLDED ARTICLE USING ULTRA-HIGH MOLECULAR WEIGHT ETHYLENE-BASED COPOLYMER POWDER

Asahi Kasei Kabushiki Kai...

1. An ultra-high molecular weight ethylene-based copolymer powder comprising:an ethylene unit and an ?-olefin unit having 3 or more and 8 or less carbon atoms as structural units,
wherein the ultra-high molecular weight ethylene-based copolymer powder has a viscosity-average molecular weight of 100,000 or more and 10,000,000 or less,
a content of the ?-olefin unit is 0.01 mol % or more and 0.10 mol % or less based on a total amount of the ethylene unit and the ?-olefin unit, and
in measurement with a differential scanning calorimeter under following conditions, an isothermal crystallization time is determined as a time from reaching 126° C. of Step A3 as a starting point (0 min) to giving an exothermic peak top due to crystallization and the isothermal crystallization time is 5 minutes or more (Conditions for measurement of isothermal crystallization time);
Step A1: holding at 50° C. for 1 minute and then an increase up to 180° C. at a temperature rise rate of 10° C./min,
Step A2: holding at 180° C. for 30 minutes and then a decrease down to 126° C. at a temperature drop rate of 80° C./min, and
Step A3: holding at 126° C.
US Pat. No. 10,337,100

SPUTTERING TARGET COMPRISING NI—P ALLOY OR NI—PT—P ALLOY AND PRODUCTION METHOD THEREFOR

1. A method of producing a Ni—P alloy sputtering target, wherein a Ni—P alloy containing 15 to 17 wt % of P and remainder being Ni and unavoidable impurities is melted and atomized to prepare a Ni—P alloy atomized powder having an average grain size of 100 ?m or less, the Ni—P alloy atomized powder is mixed with a Ni atomized powder, and the obtained mixed powder is hot pressed to produce a sintered compact containing 1 to 10 at % of P and a remainder of Ni and unavoidable impurities.
US Pat. No. 10,336,845

LOW ETHYLENE AMORPHOUS PROPYLENE-ETHYLENE-DIENE TERPOLYMER COMPOSITIONS

ExxonMobil Chemical Paten...

1. A propylene-ethylene-diene terpolymer comprising from 2% to 25% by weight of ethylene, from 98% to 75% by weight propylene and from 1% to 21% by weight of a diene, wherein the terpolymer has a crystallinity of less than 3%, a melt flow rate (MFR) of less than 10 g/10 min, and a Tg by DSC of from ?2° C. to ?25° C., and wherein the terpolymer does not comprise isotactic polypropylene sequences.
US Pat. No. 10,336,847

VINYL CHLORIDE-BASED POLYMER, METHOD FOR PREPARING THE SAME, AND THERMOPLASTIC RESIN COMPOSITION CONTAINING THE SAME

LG CHEM, LTD., Seoul (KR...

1. A vinyl chloride-based polymer containing 0.001 parts by weight or more and less than 2 parts by weight of an unsaturated fatty acid ester on the basis of 100 parts by weight of the vinyl chloride-based polymer,wherein the vinyl chloride-based polymer comprises a vinyl chloride-based monomer and the unsaturated fatty acid ester,
wherein the vinyl chloride-based monomer is a vinyl chloride monomer alone, or a combination of a vinyl chloride monomer and a comonomer copolymerizable therewith,
wherein the comonomer is a vinyl-based monomer,
wherein the unsaturated fatty acid ester includes cis- and trans-isomers of the unsaturated fatty acid ester, and
wherein the weight ratio between the cis- and trans-isomers of the unsaturated fatty acid ester is 60:40 to 90:10.
US Pat. No. 10,334,797

MELON PLANTS WITH A DOMINANT MELON YELLOWING ASSOCIATED VIRUS (MYAV) RESISTANCE GENE

NUNHEMS B.V., Nunhem (NL...

1. A non-wild cultivated Cucumis melo plant, or part thereof, comprising resistance against Melon Yellowing associated Virus (MYaV) wherein said resistance is conferred by an introgression fragment on chromosome 6 in homozygous or heterozygous form and wherein said introgression fragment is from a wild accession of the species Cucumis melo, a representative sample of seeds of said wild accession having been deposited under accession number NCI MB 41967 or NCIMB 41968, wherein said introgression fragment comprises at least two of the following SNP markers:a) the CC or AC genotype for the Single Nucleotide Polymorphism marker mME15090 in SEQ ID NO: 1;
b) the AA or AG genotype for the Single Nucleotide Polymorphism marker mME12135 in SEQ ID NO: 3;
c) the AA or AG genotype for the Single Nucleotide Polymorphism marker mME21377 in SEQ ID NO: 8; and/or
d) the TT or CT genotype for the Single Nucleotide Polymorphism marker mME13585 in SEQ ID NO: 12.
US Pat. No. 10,334,798

MELON VARIETY NUN 16215 MEM

NUNHEMS B.V., Nunhem (NL...

1. A plant, plant part or seed of melon variety NUN 16215 MEM, wherein a representative sample of seed of said melon variety is deposited under Accession Number NCIMB 43373.
US Pat. No. 10,336,849

COPOLYMER COMPRISING OXAZOLINE MONOMERS AND USE THEREOF AS CROSSLINKER

BASF SE, Ludwigshafen (D...

1. A copolymer A, comprising:at least one monomer (a) selected from the group consisting of a C1-20-alkyl (meth)acrylate, a C8-20-vinylaromatic, and a combination thereof;
at least one ethylenically unsaturated monomer (b), which comprises at least one sulfonic acid group (—SO3M), wherein M is one or more metals;
at least one ethylenically unsaturated monomer (c), which comprises at least one oxazoline group;
and optionally at least one further monomer (d) and/or additive,
wherein a fraction of the monomers (b) and (c) is in total less than 50% by weight, based on the total amount of the monomers in the copolymer A, and
wherein the copolymer A is a water-soluble polymer having a solubility in water of at least 100 g/l.
US Pat. No. 10,334,799

HYBRID TOMATO VARIETY H1765

H.J. Heinz Company Brands...

1. Tomato seed designated as ‘H1765’, representative sample of seed having been deposited under ATCC Accession Number PTA-124675.
US Pat. No. 10,334,800

VARIETY CORN LINE KID4330

Syngenta Participations A...

1. A seed of maize variety KID4330, wherein representative seed of said maize variety KID4330 has been deposited under ATCC Accession Number PTA-124542.
US Pat. No. 10,334,801

SOYBEAN VARIETY SM14328903

Agrigenetics, Inc., Indi...

1. A seed of soybean variety SM14328903, wherein a representative sample of the seed having been deposited under ATCC Accession No. PTA-123575.
US Pat. No. 10,334,802

MAIZE HYBRID X00M487

PIONEER HI-BRED INTERNATI...

1. A seed of hybrid maize variety X00M487, representative seed produced by crossing a first plant of variety PH42WT with a second plant of variety PH1W4R, wherein representative seed of the varieties PH42WT and PH1W4R have been deposited under ATCC Accession Numbers PTA-124778 and PTA-121351, respectively.
US Pat. No. 10,336,853

POLYMER, PROCESS AND COMPOSITION

DSM IP ASSETS B.V., Heer...

1. A process for preparing a copolymer having a low molecular weight and high glass transition temperature, wherein the process comprises conducting a solution polymerisation process of a monomer composition comprising:(a) from 20 to 80 wt-% of at least one itaconate functional monomer not containing acidic groups or precursor acid groups,
(b) not more than 40 wt-% of an acid functional monomer in an amount sufficient to achieve an acid value from 160 to 325 mg KOH per g of solid copolymer, and
(c) optionally not more than 72 wt. % of monomers other than monomers (a) or (b); wherein
the weight percentages of monomers (a), (b) and (c) total 100% and are calculated as a proportion of the total amount of monomers in the copolymer being 100%; and with the provisos:
(I) the copolymer has a number average molecular weight (Mn) of no more than 15 kilograms per mole; and
(II) the copolymer has a glass transition temperature of at least 75° C., and
(III) the copolymer contains less than 40 wt-% vinyl aromatic monomer; and optionally
(IV) the copolymer contains less than 40 wt-% methacrylate monomer.
US Pat. No. 10,334,803

MAIZE HYBRID X95M224

PIONEER HI-BRED INTERNATI...

1. A seed of hybrid maize variety X95M224, representative seed produced by crossing a first plant of variety PH259Y with a second plant of variety PH2RRS, wherein representative seed of the varieties PH259Y and PH2RRS have been deposited under ATCC Accession Numbers PTA-122443 and PTA-124303, respectively.
US Pat. No. 10,336,854

ALKOXYSILANE-FUNCTIONALIZED AND ALLOPHANATE-FUNCTIONALIZED URETHANES

Evonik Degussa GmbH, Ess...

1. An alkoxysilane-functionalized and allophanate-functionalized urethane comprising the reaction product ofat least one alkoxysilane group-containing monourethane A) of formula 1
Rn(OR1)3-nSi—R2—NH—(C?O)—OR3  formula 1
where Rn, R1, and R3 are each independently hydrocarbyl radicals having 1-8 carbon atoms, which may be linear, branched or cyclic, or else may be integrated together to form a cyclic system, and n is 0-2,
R2 is a diradical having 1-8 carbon atoms, which may be linear, branched or cyclic, or else may be integrated together to form a cyclic system,
and
at least one diisocyanate B),
in a molar ratio of A) to B) of from 1.0:1.5 to 1.0:0.6,
optionally in the presence of at least one catalyst K),
and the subsequent the at least one reaction product
with at least one diol and/or polyol C),
optionally in the presence of at least one catalyst K),
in the ratio of the NCO groups of the at least one reaction product to the OH groups of the diol and/or polyol C of from 1.0:1.5 to 1.0:0.6.
US Pat. No. 10,337,110

DEVICE AND METHOD FOR THE FLEXIBLE USE OF ELECTRICITY

Covestro Deutschland AG, ...

1. A method for flexible use of electrical power, wherein chlorine is produced by chlor-alkali electrolysis in a device comprising an electrolysis cell for chlor-alkali electrolysis having an anode half-cell, a cathode half-cell and a cation exchange membrane that separates the anode half-cell and the cathode half-cell from one another, an anode arranged in the anode half-cell for evolution of chlorine, an oxygen-consuming electrode arranged in the cathode half-cell as cathode, and a conduit for supply of gaseous oxygen to the cathode half-cell, wherein the device has at least one conduit for purging of the cathode half-cell with inert gas and wherein:a) when power supply is low, the oxygen-consuming electrode is supplied with gaseous oxygen, and oxygen is reduced at the oxygen-consuming electrode at a first cell voltage; and
b) when power supply is high, the oxygen-consuming electrode is not supplied with oxygen, and hydrogen is generated at the cathode at a second cell voltage which is higher than the first cell voltage.
US Pat. No. 10,334,804

PLANTS AND SEEDS OF HYBRID CORN VARIETY CH464053

Monsanto Technology LLC, ...

1. A seed of hybrid corn variety CH464053, produced by crossing a first plant of variety CV691450 with a second plant of variety CV759867, wherein representative seeds of said varieties CV691450 and CV759867 are deposited under ATCC Accession Nos. PTA-125241 and PTA-124497, respectively.
US Pat. No. 10,336,855

AQUEOUS PEPTIDE-FUNCTIONALIZED POLYURETHANE DISPERSIONS

Max-Planck-Gesellschaft Z...

1. A process for manufacturing a peptide-functionalized polyurethane dispersion (PUD), comprising:(1) providing an NCO-terminated polyurethane prepolymer;
(2) reacting said NCO-terminated polyurethane prepolymer with a compound comprising at least one NCO-reactive group and at least one maleimide group to obtain a maleimide-terminated polyurethane prepolymer;
(3) dispersing said maleimide-terminated polyurethane prepolymer into a continuous aqueous phase; and
(4) reacting the maleimide-terminated polyurethane prepolymer with one or more peptides, wherein said one or more peptides comprise amino acid side chains reactive with the maleimide group, thereby forming peptide-functionalized polyurethane particles.
US Pat. No. 10,334,805

PLANTS AND SEEDS OF HYBRID CORN VARIETY CH818252

Monsanto Technology LLC, ...

1. A seed of hybrid corn variety CH818252, produced by crossing a first plant of variety CV730108 with a second plant of variety CV644326, wherein representative seeds of said varieties CV730108 and CV644326 are deposited under ATCC Accession Nos. PTA-124485 and PTA-125218, respectively.
US Pat. No. 10,336,856

ALKOXYSILANE- AND ALLOPHANATE-FUNCTIONALIZED COATING MATERIALS

Evonik Degussa GmbH, Ess...

1. An alkoxysilane-functionalized and allophanate-functionalized coating material comprisinga) a binder component of 10-99 wt % of at least one reaction product of
one an alkoxysilane-containing monourethane A) of formula 1
Rn(OR1)3-nSi—R2—NH—(C?O)—OR3  formula 1
wherein R, R1, and R3 independently of one another represent hydrocarbon radicals, and R2 is a diradical, having 1-8 carbon atoms, wherein these may be linear, branched or cyclic or else may be integrated together to form a cyclic system, and n represents 0-2, and
a diisocyanate B),
optionally in the presence of at least one catalyst K),
in a molar ratio of A) to B) of from 1.0:1.5 to 1.0:0.6,
II,
and subsequent reaction of the at least one reaction product
with at least one diol and/or polyol C),
in the presence of at least one catalyst K),
in a ratio of NCO groups of reaction product to OH groups of the diol and/or polyol C) of from 1.0:1.5 to 1.0:0.6;
b) from 1-90 wt % of a hydroxyl-containing or amino-containing binder component,
c) from 0-50 wt % of at least one aromatic, aliphatic or cycloaliphatic polyisocyanate having an NCO functionality of at least 2,
d) from 0-5 wt % of at least one catalyst,
wherein a)-d) add up to 100 wt %,
e) optionally auxiliaries and/or additives,
f) optionally solvents.